Search

Your search keyword '"Siranoush Manoukian"' showing total 252 results
Start Over Author "Siranoush Manoukian"
252 results on '"Siranoush Manoukian"'

151. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs)

Author

Stacey L. Edwards, Daniel Vincent, Antoinette Hollestelle, Melissa C. Southey, Thilo Dörk, Jonine Figueroa, Robert Winqvist, Wei Zheng, Keitaro Matsuo, Fergus J. Couch, Don M. Conroy, Anna Jakubowska, Paul D.P. Pharoah, Sara Margolin, Simon S. Cross, Joe Dennis, Rebecca Mayes, Annegien Broeks, Mitul Shah, Matthias W. Beckmann, Mahdi Moradi Marjaneh, Pei-Ei Wu, Javier Benitez, Hanna Fues Wahl, Ute Hamann, Rita K. Schmutzler, Guillermo Pita, Nichola Johnson, Suleeporn Sangrajrang, James McKay, Barbara Burwinkel, Hoda Anton-Culver, Pascal Guénel, Douglas F. Easton, Veli-Matti Kosma, Hidemi Ito, Angela Cox, Georgia Chenevix-Trench, M. Rosario Alonso, Mark S. Goldberg, Hatef Darabi, Volker Arndt, Qin Wang, Manjeet K. Bolla, Nick Orr, Soo Hwang Teo, Soo-Chin Lee, Penny Soucy, Jonathan Beesley, Paolo Peterlongo, Ji Yeob Choi, Anthony J. Swerdlow, Jacques Simard, Kamila Czene, Anna González-Neira, Jenny Chang-Claude, Heli Nevanlinna, Ian Tomlinson, Thérèse Truong, Chen-Yang Shen, Harald Surowy, Henrik Flyger, Marjanka K. Schmidt, Graham G. Giles, John L. Hopper, Celine M. Vachon, Olivia Fletcher, Stig E. Bojesen, Mikael Hartman, Arnaud Droit, Per Hall, Cheng Har Yip, Maya Ghoussaini, Artitaya Lophatananon, Mieke Kriege, Anna H. Wu, Siranoush Manoukian, Kyriaki Michailidou, Christopher A. Haiman, Roger L. Milne, Xiao-Ou Shu, Daniel O. Stram, Katri Pylkäs, Sofia Khan, Irene L. Andrulis, Annika Lindblom, Emily Hallberg, Diana Torres, Anja Rudolph, Arto Mannermaa, Hermann Brenner, Vessela N. Kristensen, Daehee Kang, Caroline Seynaeve, Elinor J. Sawyer, Silje Nord, Hiltrud Brauch, Jan Lubinski, Natalia Bogdanova, Juliet D. French, Susan L. Neuhausen, Montserrat Garcia-Closas, Thomas Brüning, Loic Le Marchand, Peter A. Fasching, Diether Lambrechts, Daniel C. Tessier, Peter Devilee, Eva Galle, Alfons Meindl, Alison M. Dunning, Siddhartha Kar, Kenneth Muir, Curtis Olswold, Wang, Jean [0000-0002-9139-0627], Dennis, Joe [0000-0003-4591-1214], Easton, Douglas [0000-0003-2444-3247], Pharoah, Paul [0000-0001-8494-732X], Dunning, Alison [0000-0001-6651-7166], Apollo - University of Cambridge Repository, Department of Obstetrics and Gynecology, Clinicum, School of Medicine / Clinical Medicine, Cancer Research UK (Reino Unido), European Research Council, NIH - National Cancer Institute (NCI) (Estados Unidos), Post-cancer GWAS Initiative, Dutch Cancer Society (Holanda), Biobanking and BioMolecular resources Research Infrastructure (Países Bajos), Instituto de Salud Carlos III, Finlands Akademi (Finlandia), Ministry of Education, Culture, Sports, Science, and Technology (Japón), Japan Agency for Medical Research and Development, United States Army Medical Research and Development Command, California Breast Cancer Research Program, Stichting tegen Kanker, Deutsche Krebshilfe, National Health and Medical Research Council (Australia), Ministry of Economic Development, Innovation and Export Trade, Ministry of Higher Education (Malasia), Agency for Science, Technology and Research (Singapur), National Medical Research Council (Singapur), The Research Council of Norway, Southern and Eastern Norway Regional Health Authority, Finnish Cancer (Center of Excellence grant), Genetic Associations and Mechanisms in Oncology (GAME-ON) Initiative, Yorkshire Cancer Research, BRL (Basic Research Laboratory) program through the National Research Foundation of Korea - Ministry of Education, Science and Technology, NIH - National Cancer Institute (NCI). Specialized Programs of Research Excellence (SPOREs) (Estados Unidos), Hellenic Cooperative Oncology Group research grant, Institute of Cancer Research (Reino Unido), United States of Department of Health & Human Services, Medical Oncology, and Obstetrics & Gynecology

Subjects
0301 basic medicine, Vesicular Transport Proteins, Genome-wide association study, 0302 clinical medicine, Breast cancer, Genetics research, Medicine and Health Sciences, HUMAN GENOME, Genetics, Multidisciplinary, Chromosome Mapping, ASSOCIATION, Tag SNP, 3. Good health, 030220 oncology & carcinogenesis, Female, EXPRESSION, SUSCEPTIBILITY LOCI, Genotype, European Continental Ancestry Group, 3122 Cancers, Quantitative Trait Loci, Locus (genetics), Single-nucleotide polymorphism, Breast Neoplasms, Biology, Polymorphism, Single Nucleotide, Article, White People, REGION, RC0254, 03 medical and health sciences, SDG 3 - Good Health and Well-being, REVEALS, medicine, SNP, Humans, Genetic Predisposition to Disease, FUNCTIONAL VARIANTS, Genetic association, RISK LOCUS, CONSORTIUM, medicine.disease, ENHANCERS, 030104 developmental biology, Risk factors, Imputation (genetics), Chromosomes, Human, Pair 17, Genome-Wide Association Study
Abstract

Genome-wide association studies have found SNPs at 17q22 to be associated with breast cancer risk. To identify potential causal variants related to breast cancer risk, we performed a high resolution fine-mapping analysis that involved genotyping 517 SNPs using a custom Illumina iSelect array (iCOGS) followed by imputation of genotypes for 3,134 SNPs in more than 89,000 participants of European ancestry from the Breast Cancer Association Consortium (BCAC). We identified 28 highly correlated common variants, in a 53 Kb region spanning two introns of the STXBP4 gene, that are strong candidates for driving breast cancer risk (lead SNP rs2787486 (OR = 0.92; CI 0.90–0.94; P = 8.96 × 10−15)) and are correlated with two previously reported risk-associated variants at this locus, SNPs rs6504950 (OR = 0.94, P = 2.04 × 10−09, r2 = 0.73 with lead SNP) and rs1156287 (OR = 0.93, P = 3.41 × 10−11, r2 = 0.83 with lead SNP). Analyses indicate only one causal SNP in the region and several enhancer elements targeting STXBP4 are located within the 53 kb association signal. Expression studies in breast tumor tissues found SNP rs2787486 to be associated with increased STXBP4 expression, suggesting this may be a target gene of this locus., published version, peerReviewed

Published
2016
Full Text
View/download PDF

152. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Author

Kenneth Offit, D. Gareth Evans, Dominique Stoppa-Lyonnet, Edith Olah, Nadine Tung, Andrew K. Godwin, Irene L. Andrulis, Jeffrey N. Weitzel, Eitan Friedman, Gord Glendon, Mary B. Daly, Kathleen Claes, Laima Tihomirova, Bella Kaufman, kConFab Investigators, Aleksandra Tołoczko-Grabarek, Katarzyna Jaworska-Bieniek, Fergus J. Couch, Jonathan Carter, Ute Hamann, Embrace, Emily Hallberg, Olufunmilayo I. Olopade, Niklas Loman, Claudine Isaacs, Raanan Berger, Caroline Seynaeve, Patricia A. Ganz, Trinidad Caldés, Jenny Lester, Steve Ellis, Fei Wan, Stephanie Chen, Cezary Cybulski, Saundra S. Buys, Åke Borg, Jamal Zidan, Matti A. Rookus, Javier Benitez, Csilla Szabo, Gillian Mitchell, Douglas F. Easton, Jocelyne Chiquette, Katherine L. Nathanson, Mary Beth Terry, Kristin K. Zorn, Danylo Villano, Mads Thomassen, Nandita Mitra, Mariella Tancredi, Conxi Lázaro, Hebon, Jacek Gronwald, Paolo Radice, Katarzyna Durda, Pascaline Berthet, Shan Wang-Gohrke, Orland Diez, Siranoush Manoukian, Amanda E. Toland, Ava Kwong, Barbara Wappenschmidt, Tara M. Friebel, Lenka Foretova, Beth Y. Karlan, Marco Montagna, Yael Laitman, Georgia Chenevix-Trench, Antonis C. Antoniou, Paraskevi Apostolou, Susan J. Ramus, Jacques Simard, Daniel Barrowdale, Timothy R. Rebbeck, Thomas Hansen, Jan Lubinski, Manuel R. Teixeira, Eric Hahnen, Grzegorz Sukiennicki, Christine Lasset, Sue K. Park, Christian F. Singer, Debra Frost, Elizabeth J. van Rensburg, Esther M. John, Susan L. Neuhausen, Lesley McGuffog, Dieter Niederacher, Penny Soucy, Heli Nevanlinna, Judy Garber, Norbert Arnold, Robert L. Nussbaum, Susan M. Domchek, Melissa C. Southey, Ramunas Janavicius, Mark H. Greene, Anna Jakubowska, Marc Tischkowitz, Christine Rappaport-Fuerhauser, Marion Piedmonte, Miguel de la Hoya, Soo Hwang Teo, Evgeny N. Imyanitov, Banu Arun, Hematology, Medical Oncology, Tischkowitz, Marc [0000-0002-7880-0628], Easton, Douglas [0000-0003-2444-3247], Antoniou, Antonis [0000-0001-9223-3116], Apollo - University of Cambridge Repository, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Department of Obstetrics and Gynecology, and Clinicum

Subjects
DOUBLE HETEROZYGOSITY, 0301 basic medicine, endocrine system diseases, Genes, BRCA2, Genes, BRCA1, CANCER SUSCEPTIBILITY GENE, Loss of Heterozygosity, Estrogen receptor, medicine.disease_cause, Loss of heterozygosity, 0302 clinical medicine, Breast cancer, 3123 Gynaecology and paediatrics, Medicine and Health Sciences, Medicine, Promoter Regions, Genetic, skin and connective tissue diseases, SPORADIC BREAST-CANCER, Medicine(all), Mutation, UNKNOWN CLINICAL-SIGNIFICANCE, Exons, GERMLINE MUTATIONS, female genital diseases and pregnancy complications, transheterozygosity, 3. Good health, Phenotype, Population Surveillance, WILD-TYPE CHROMOSOME, 030220 oncology & carcinogenesis, Female, Transheterozygosity, Research Article, Heterozygote, medicine.medical_specialty, 3122 Cancers, Hereditary breast and ovarian cancer, Breast Neoplasms, DNA-SEQUENCE VARIANTS, hereditary breast and ovarian cancer, OVARIAN-CANCER, Càncer de mama, SPORADIC, 03 medical and health sciences, Germline mutation, GERMLINE, Progesterone receptor, Humans, BREAST-CANCER, Allele, neoplasms, Alleles, Germ-Line Mutation, Gynecology, MUTATIONS, business.industry, Biology and Life Sciences, medicine.disease, BRCA1, BRCA2, HETEROGENIC LOSS, 030104 developmental biology, FANCONI-ANEMIA, business, Ovarian cancer
Abstract

BACKGROUND: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). 'Cases' were defined as TH, and 'controls' were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 'controls' carried a BRCA1 mutation found in the TH 'case'. Matched SH2 'controls' carried a BRCA2 mutation found in the TH 'case'. After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. RESULTS: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p, published_or_final_version

Published
2016
Full Text
View/download PDF

153. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup

Author

Maurizio Lombardo, Alessandra Farnetti, Monica Rodolfo, G. Ghigliotti, Giovanna Bianchi-Scarrà, Paola Queirolo, Lorenzo Borgognoni, Vincenzo De Giorgi, Anna M aria Ronco, Lorenza Pastorino, Francesca Gensini, G. Imberti, Mario Mandalà, Marisa Muggianu, Francesco Spagnolo, Virginia Andreotti, Antonella Vecchiato, Lisa Elefanti, Fabrizio Ayala, Claudia Martinuzzi, Alessandro Testori, Paola Ghiorzo, Siranoush Manoukian, Chiara Menin, Maria Grazia Tibiletti, Enrica Teresa Tanda, William Bruno, Andrea Maurichi, Giuseppe Palmieri, Virginia Picasso, Chiara Astrua, Paola Savoia, Paolo A. Ascierto, Imma Savarese, Camilla Stagni, and Giuseppe Spadola

Subjects
0301 basic medicine, Oncology, microphthalmia-associated transcription factor, Mutation rate, Skin Neoplasms, cyclin-dependent kinase inhibitor 2A, pancreatic cancer, Neoplasms, Multiple Primary, 0302 clinical medicine, Mutation Rate, CDKN2A, Multiple Primary, Neoplasms, 80 and over, Family history, Aged, 80 and over, family history, Melanoma, Middle Aged, cyclin-dependent kinase, Italy, suscettibilità genetica, 030220 oncology & carcinogenesis, genetic assessment, Adult, medicine.medical_specialty, Adolescent, Genetic counseling, Genetic Counseling, Dermatology, 03 medical and health sciences, Young Adult, Germline mutation, Pancreatic cancer, Internal medicine, melanoma, mutation, Aged, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase Inhibitor p16, Germ-Line Mutation, Humans, Microphthalmia-Associated Transcription Factor, Patient Selection, 2708, medicine, neoplasms, melanoma, genetics, business.industry, Cancer, medicine.disease, 030104 developmental biology, Cancer research, business
Abstract

Background Multiple primary melanoma (MPM), in concert with a positive family history, is a predictor of cyclin-dependent kinase (CDK) inhibitor 2A ( CDKN2A ) germline mutations. A rule regarding the presence of either 2 or 3 or more cancer events (melanoma and pancreatic cancer) in low or high melanoma incidence populations, respectively, has been established to select patients for genetic referral. Objective We sought to determine the CDKN2A / CDK4 /microphthalmia-associated transcription factor mutation rate among Italian patients with MPM to appropriately direct genetic counseling regardless of family history. Methods In all, 587 patients with MPM and an equal number with single primary melanomas and control subjects were consecutively enrolled at the participating centers and tested for CDKN2A , CDK4 , and microphthalmia-associated transcription factor. Results CDKN2A germline mutations were found in 19% of patients with MPM versus 4.4% of patients with single primary melanoma. In familial MPM cases the mutation rate varied from 36.6% to 58.8%, whereas in sporadic MPM cases it varied from 8.2% to 17.6% in patients with 2 and 3 or more melanomas, respectively. The microphthalmia-associated transcription factor E318K mutation accounted for 3% of MPM cases altogether. Limitations The study was hospital based, not population based. Rare novel susceptibility genes were not tested. Conclusion Italian patients who developed 2 melanomas, even in situ, should be referred for genetic counseling even in the absence of family history.

Published
2016
Full Text
View/download PDF

154. Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis

Author

Katherine L. Nathanson, Edson Rondinelli, Andrej Sali, Rosane Silva, Marcelo A. Carvalho, Siranoush Manoukian, Paolo Radice, Rachel Karchin, Sylvia M. Marsillac, Rebecca Sutphen, Jennifer L. Pickard-Brzosowicz, David E. Goldgar, Alvaro N.A. Monteiro, Luis Gayol, Fergus J. Couch, Turán P. Ürményi, Lisa Baumbach, Ramona F. Swaby, and Scott Grist

Subjects
Cancer Research, endocrine system diseases, Tumor suppressor gene, Genes, BRCA1, Mutation, Missense, Biology, medicine.disease_cause, Article, Structure-Activity Relationship, Germline mutation, Polymorphism (computer science), Genotype, medicine, Animals, Humans, Missense mutation, Genetic Predisposition to Disease, skin and connective tissue diseases, Gene, Germ-Line Mutation, Genetics, Mutation, BRCA1 Protein, Genetic Variation, Cancer, medicine.disease, Oncology
Abstract

Germ line inactivating mutations in BRCA1 confer susceptibility for breast and ovarian cancer. However, the relevance of the many missense changes in the gene for which the effect on protein function is unknown remains unclear. Determination of which variants are causally associated with cancer is important for assessment of individual risk. We used a functional assay that measures the transactivation activity of BRCA1 in combination with analysis of protein modeling based on the structure of BRCA1 BRCT domains. In addition, the information generated was interpreted in light of genetic data. We determined the predicted cancer association of 22 BRCA1 variants and verified that the common polymorphism S1613G has no effect on BRCA1 function, even when combined with other rare variants. We estimated the specificity and sensitivity of the assay, and by meta-analysis of 47 variants, we show that variants with 50% can be classified as neutral. In conclusion, we did functional and structure-based analyses on a large series of BRCA1 missense variants and defined a tentative threshold activity for the classification missense variants. By interpreting the validated functional data in light of additional clinical and structural evidence, we conclude that it is possible to classify all missense variants in the BRCA1 COOH-terminal region. These results bring functional assays for BRCA1 closer to clinical applicability. [Cancer Res 2007;67(4):1494–501]

Published
2007
Full Text
View/download PDF

155. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families

Author

Gabriella Della-Torre, Monica Terenziani, Marco A. Pierotti, Paolo Radice, Monica Barile, Laura Cortesi, Silvia Stacchiotti, Bernard Peissel, Valeria Pensotti, Siranoush Manoukian, Graziella Pasquini, Floriana Barbera, and Simona Frigerio

Subjects
Male, Cancer Research, endocrine system diseases, Tumor suppressor gene, Genes, BRCA2, Genes, BRCA1, Mutation, Missense, Breast Neoplasms, Biology, medicine.disease_cause, Polymerase Chain Reaction, Germline, Germline mutation, Breast cancer, medicine, Humans, skin and connective tissue diseases, neoplasms, Germ-Line Mutation, Mutation, Sarcoma, Genes, p53, medicine.disease, Pedigree, Oncology, Li–Fraumeni syndrome, Cancer research, Female, Ovarian cancer
Abstract

The genetic aetiology of familial aggregations of breast cancer and sarcomas has been elucidated only in part. In this study, 23 unrelated individuals from families with one case of sarcoma and at least one case of breast cancer were screened for mutations in the TP53, BRCA1 and BRCA2 genes. Families were classified according to their conformity to the criteria defining the Li-Fraumeni syndrome (LFS), Li-Fraumeni-like (LFL) syndrome and hereditary breast/ovarian cancer (HBOC). Germline TP53 mutations were identified in three instances (13%), including one LFS and two LFL families, while none of the non-LFS/non-LFL families had a TP53 mutation. Three cases (13%), including one with a TP53 mutation, carried BRCA2 mutations. Of these, two were observed in LFL/HBOC families and the other one in a non-LFS/non-LFL/HBOC family, while none of the non-HBOC families tested positive. These findings suggest that the screening of BRCA2, in addition to TP53, may be appropriate for the molecular characterisation of breast cancer/sarcoma families, with practical implications for counselling and clinical management.

Published
2007
Full Text
View/download PDF

156. Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk

Author

Martine Tranchant, Fergus J. Couch, Meeri Otsukka, Sabine Behrens, Jirong Long, Nadia Obi, Kamila Czene, John L. Hopper, Heather Thorne, Robert Pilarski, Anja Rudolph, Simon S. Cross, Volker Harth, Gabrielle Colleran, Hatef Darabi, Thomas Van Brussel, Eunjung Lee, Anne Lotz, E. Krol-Warmerdam, M. Pilar Zamora, Qin Wang, Andy C. H. Lee, Annie Fung, Kara Sargus, Melissa C. Southey, Katja Butterbach, Nuria Álvarez, Francois Bacot, Jeffrey G. Meyer, Ian W. Brock, Jessica Clague De Hart, Pierre Laurent-Puig, Irene L. Andrulis, Pei Chao, Arnaud Droit, Per Hall, Daniel C. Tessier, Paolo Radice, Frederic Robidoux, Don M. Conroy, Irja Erkkilä, Daniel Vincent, Antoinette Hollestelle, Christopher A. Hilker, Alicia Beeghly-Fadiel, Muhabbet Celik, Peggy Reynolds, Caroline Baynes, Sophia S. Wang, Katri Pylkäs, Kang In Nee, Robert Winqvist, Henrik Flyger, Annette Heemskerk, Sara Margolin, Hui Cai, Julie M. Cunningham, Prat Boonyawongviroj, Bernardo Bonanni, Anthony J. Swerdlow, Dan Connley, Huiyan Ma, Valerie Gaborieau, David O. Nelson, Keitaro Matsuo, Sylvie La Boissière, Pornthep Siriwanarungsan, Hidemi Ito, Ursula Eilber, Matthias W. Beckmann, Sylvia Rabstein, Natalia Bogdanova, Anna Jakubowska, Yves Raoul, Robert A.E.M. Tollenaar, Frans B. L. Hogervorst, Hannah L Park, Pierre Kerbrat, Ying Zheng, Paul D.P. Pharoah, Wanqing Wen, Judith Heinz, Annika Lindblom, Christa Stegmaier, Manjeet K. Bolla, Loris Bernard, Anna H. Wu, Alison M. Dunning, Hermann Brenner, A. Green, Thilo Dörk, Chia-Ni Hsiung, Dennis Deapen, Michael G. Schrauder, Gilian Peuteman, S.E. Higham, Sabapathy P. Balasubramanian, Irene Feroce, Christina Justenhoven, Angela Jones, William J. Blot, Nichola Johnson, Petra Seibold, D. Bowtell, Jiajun Shi, Wei Zheng, U Hamann, Pascal Guenel, P. Webb, Soo Hwang Teo, Daniela Zaffaroni, J. Blom, Rita K. Schmutzler, Douglas F. Easton, Yani Lu, Witold Zatonski, Phuah Sze Yee, Susan L. Neuhausen, Kenneth Muir, Sofia Khan, Daehee Kang, Silke Landrith, Helena Kemiläinen, Maggie Angelakos, Rich Pinder, Javier Benitez, Til Olchers, Senno Verhoef, Fred Schumacher, Martha J. Shrubsole, Teresa Selander, Teh Yew Ching, Christof Sohn, Patrick Arveux, Dorota M. Gertig, Saila Kauppila, Mervi Grip, Florentia Fostira, Jenny Chang-Claude, Michael Stagner, Kathleen Corthouts, Ellen Van Der Schoot, H Nevanlinna, Peter Bugert, Christian Baisch, Eija Myöhänen, Sonja Wolf, Hoda Anton-Culver, Nicola Miller, Cheng Har Yip, Neonila Szeszenia-Dabrowska, Nicholas K. Hayward, Dieter Flesch-Janys, Barbara Burwinkel, J. Molenaar, Eileen Williams, Marjanka K. Schmidt, Yon Ko, Anja Nieuwlaat, Chen-Yang Shen, Veli-Matti Kosma, Ian Tomlinson, Thérèse Truong, Amanda E. Toland, Artitaya Lophatananon, Mikael Hartman, Jonathan Beesley, Bernard Peissel, Paolo Peterlongo, Ji Yeob Choi, Craig Luccarini, Rosalind A. Eeles, Niall M. McInerney, Bernard Thienpont, Xiao-Ou Shu, Léa Héguy, Maya Ghoussaini, Sander Canisius, Wing-Yee Lo, Suleeporn Sangrajrang, Nur Aishah Taib, June Yashiki, Kirsimari Aaltonen, Louise A. Brinton, Elinor J. Sawyer, Alina Vrieling, Angela Cox, Frederik Marmé, Matthias Rübner, Graham G. Giles, Sonja Oeser, Hans Christiansen, Andrew Rowan, Ed Dicks, Andeas Schneeweiß, Catriona McLean, Antonis C. Antoniou, B. Pesch, Eveline Niedermayr, Volker Arndt, Janet E. Olson, Dominiek Smeets, Jingmei Li, Georgia Chenevix-Trench, Claire Mulot, Siranoush Manoukian, Hans Fischer, Ellen Crepin, Arto Mannermaa, Ali Amin Al Olama, Helen Cramp, Ans M.W. van den Ouweland, Olivia Fletcher, Sharon A. Windebank, Peter Hillemanns, Nayana Weerasooriya, James V. Lacey, Leslie Bernstein, Romuald Le Scodan, Giulietta Scuvera, P. Parsons, Thomas C. Putti, Elaine Ryder-Mills, Sara Benlloch, Beata Peplonska, Stig E. Bojesen, Kimberley Chua, Stefan Nickels, Nick Orr, Roger L. Milne, Tuomas Heikkinen, Christopher A. Haiman, Natalia Antonenkova, Volker Hermann, Maria Kabisch, Kenneth Offit, Julia A. Knight, Angela Maniscalco, Arja Jukkola-Vuorinen, Hartwig Ziegler, Chenjie Zeng, Jacques Simard, Pamela L. Horn-Ross, Daphne S.C. Lee, Xingyi Guo, Jan Lubinski, Michael J. Kerin, Loic Le Marchand, Sune F. Nielsen, Peter Devilee, A. De Fazio, Qiuyin Cai, Annie Turgeon, Yoon Sook-Yee, Silje Nord, Petra Bos, Hiltrud Brauch, Kyriaki Michailidou, Shivaani Mariapun, Kari Mononen, Alfons Meindl, Peter B. Kang, Siddhartha Kar, Alessandra Rossi, G. Chenevix-Trench, Diether Lambrechts, Karl von Smitten, Zsofia Kote-Jarai, Emiel J. Th. Rutgers, Chiu-Chen Tseng, Peter A. Fasching, Lesley McGuffog, Annegien Broekss, Johann H. Karstens, Montserrat Garcia-Closas, Thomas Brüning, David C. Whiteman, Judi Maskiell, Clinical Genetics, Cardiothoracic Surgery, Medical Oncology, and Obstetrics & Gynecology

Subjects
Genetic Markers, Linkage disequilibrium, Epidemiology, Locus (genetics), Genome-wide association study, Breast Neoplasms, Biology, Polymorphism, Single Nucleotide, Article, Breast cancer, SDG 3 - Good Health and Well-being, Risk Factors, medicine, Humans, Genetic Predisposition to Disease, Gene, Genetics, Molecular epidemiology, Case-control study, Chromosome Mapping, medicine.disease, Logistic Models, Oncology, Genetic marker, Genetic Loci, Case-Control Studies, Female, Chromosomes, Human, Pair 4, Genome-Wide Association Study
Abstract

Background: A recent association study identified a common variant (rs9790517) at 4q24 to be associated with breast cancer risk. Independent association signals and potential functional variants in this locus have not been explored. Methods: We conducted a fine-mapping analysis in 55,540 breast cancer cases and 51,168 controls from the Breast Cancer Association Consortium. Results: Conditional analyses identified two independent association signals among women of European ancestry, represented by rs9790517 [conditional P = 2.51 × 10−4; OR, 1.04; 95% confidence interval (CI), 1.02–1.07] and rs77928427 (P = 1.86 × 10−4; OR, 1.04; 95% CI, 1.02–1.07). Functional annotation using data from the Encyclopedia of DNA Elements (ENCODE) project revealed two putative functional variants, rs62331150 and rs73838678 in linkage disequilibrium (LD) with rs9790517 (r2 ≥ 0.90) residing in the active promoter or enhancer, respectively, of the nearest gene, TET2. Both variants are located in DNase I hypersensitivity and transcription factor–binding sites. Using data from both The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), we showed that rs62331150 was associated with level of expression of TET2 in breast normal and tumor tissue. Conclusion: Our study identified two independent association signals at 4q24 in relation to breast cancer risk and suggested that observed association in this locus may be mediated through the regulation of TET2. Impact: Fine-mapping study with large sample size warranted for identification of independent loci for breast cancer risk. Cancer Epidemiol Biomarkers Prev; 24(11); 1680–91. ©2015 AACR.

Published
2015

157. FANCM c.5791C > T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor

Author

Laura Ottini, Bernard Peissel, Carmen J Tartari, Peter Devilee, Silvia Tognazzo, Anders Kvist, Lara Della Puppa, Mara Colombo, Isabella Marchi, Conxi Lázaro, Caterina Vivanet, Jordi Surrallés, Valeria Viassolo, Joseph Vijai, Kenneth Offit, Paolo Radice, Veronica Medici, Ana Osorio, Francesca Spina, Stefania Tommasi, Carlo Tondini, Marina Marchetti, Chiara Corna, Eliseos J. Mucaki, Gabriele Lorenzo Capone, Piera Rizzolo, Maurizio Genuardi, Alessandra Renieri, Jan Hauke, Laura Cortesi, Laura Caleca, Dominique Stoppa-Lyonnet, Paolo Peterlongo, Christi J. van Asperen, Hans Ehrencrona, Fergus J. Couch, Ian G. Campbell, Valeria Pensotti, Irene Catucci, Miguel Angel Pujana, Sylvie Mazoyer, Massimo Federico, Paolo Verderio, Alfons Meindl, Brunella Pilato, Claus R. Bartram, Valentina Dall'Olio, Paul A. James, Massimo Bogliolo, Loris Bernard, Maria Marín, Valérie Sornin, Luisa Balestrino, Gaia Roversi, Judith Balmaña, Marie-Gabrielle Dondon, Simona Agata, Rita K. Schmutzler, Barbara Burwinkel, Viviana Gismondi, Giulia Cini, Ella R. Thompson, Nadine Andrieu, Sara Volorio, Maria Grazia Tibiletti, Francesca Damiola, Harald Surowy, Alessandra Viel, Peter K. Rogan, Laura Matricardi, Anna Laura Putignano, Cristina Verzeroli, Anna Falanga, Chiara Perfumo, Marco Montagna, Margherita Baldassarri, Monica Barile, Riccardo Dolcetti, Florentine Hilbers, Javier Benitez, Laura Papi, Maria Antonietta Mencarelli, Séverine Eon-Marchais, Gillian Mitchell, Orland Diez, Siranoush Manoukian, Maria A. Caligo, Christian Sutter, Gaetana Gambino, Xianshu Wang, Marco A. Pierotti, Bernardo Bonanni, Sara Pizzamiglio, Liliana Varesco, Valentina Silvestri, Olga M. Sinilnikova, Peterlongo, P, Catucci, I, Colombo, M, Caleca, L, Mucaki, E, Bogliolo, M, Marin, M, Damiola, F, Bernard, L, Pensotti, V, Volorio, S, Dall'Olio, V, Meindl, A, Bartram, C, Sutter, C, Surowy, H, Sornin, V, Dondon, M, Eon-Marchais, S, Stoppa-Lyonnet, D, Andrieu, N, Sinilnikova, O, Mitchell, G, James, P, Thompson, E, Kconfab, Marchetti, M, Verzeroli, C, Tartari, C, Capone, G, Putignano, A, Genuardi, M, Medici, V, Marchi, I, Federico, M, Tognazzo, S, Matricardi, L, Agata, S, Dolcetti, R, Della Puppa, L, Cini, G, Gismondi, V, Viassolo, V, Perfumo, C, Mencarelli, M, Baldassarri, M, Peissel, B, Roversi, G, Silvestri, V, Rizzolo, P, Spina, F, Vivanet, C, Tibiletti, M, Caligo, M, Gambino, G, Tommasi, S, Pilato, B, Tondini, C, Corna, C, Bonanni, B, Barile, M, Osorio, A, Benitez, J, Balestrino, L, Ottini, L, Manoukian, S, Pierotti, M, Renieri, A, Varesco, L, Couch, F, Wang, X, Devilee, P, Hilbers, F, van Asperen, C, Viel, A, Montagna, M, Cortesi, L, Diez, O, Balmaña, J, Hauke, J, Schmutzler, R, Papi, L, Pujana, M, Lázaro, C, Falanga, A, Offit, K, Vijai, J, Campbell, I, Burwinkel, B, Kvist, A, Ehrencrona, H, Mazoyer, S, Pizzamiglio, S, Verderio, P, Surralles, J, Rogan, P, and Radice, P

Subjects
DNA Repair, Heterogeneous Nuclear Ribonucleoprotein A1, DNA Mutational Analysis, Gene Expression, medicine.disease_cause, Settore MED/03 - GENETICA MEDICA, 0302 clinical medicine, Gene Frequency, Risk Factors, Genetics, Genetics (clinical), Molecular Biology, Genotype, Heterogeneous-Nuclear Ribonucleoprotein Group A-B, FANCM, Age of Onset, 0303 health sciences, Mutation, Association Studies Articles, General Medicine, Exons, Middle Aged, 3. Good health, ddc, Codon, Nonsense, 030220 oncology & carcinogenesis, Female, Protein Binding, Adult, Alleles, Binding Sites, Breast Neoplasms, Case-Control Studies, DNA Helicases, Genetic Association Studies, Genetic Predisposition to Disease, Humans, Meta-Analysis as Topic, Nucleotide Motifs, Position-Specific Scoring Matrices, Young Adult, Alternative Splicing, PALB2, Nonsense mutation, Biology, breast cancer, risk factor, 03 medical and health sciences, Breast cancer, T+nonsense+mutation+%28rs144567652%22">FANCM c.5791C>T nonsense mutation (rs144567652, medicine, Risk factor, Codon, 030304 developmental biology, medicine.disease, Exon skipping, FANCM, familial breast cancer, Nonsense, Cancer research
Abstract

© The Author 2015. Published by Oxford University Press. All rights reserved. Numerous genetic factors that influence breast cancer risk are known. However, approximately two-thirds of the overall familial risk remain unexplained. To determine whether some of the missing heritability is due to rare variants conferring high to moderate risk, we tested for an association between the c.5791C>T nonsense mutation (p. Arg1931*; rs144567652) in exon 22 of FANCM gene and breast cancer. An analysis of genotyping data from 8635 familial breast cancer cases and 6625 controls from different countries yielded an association between the c.5791C>T mutation and breast cancer risk [odds ratio (OR) = 3.93 (95% confidence interval (CI) = 1.28-12.11; P = 0.017)]. Moreover, we performed two meta-analyses of studies from countries with carriers in both cases and controls and of all available data. These analyses showed breast cancer associations with OR = 3.67 (95% CI = 1.04-12.87; P = 0.043) and OR = 3.33 (95% CI = 1.09-13.62; P = 0.032), respectively. Based on information theory-based prediction, we established that the mutation caused an out-of-frame deletion of exon 22, due to the creation of a binding site for the pre-mRNA processing protein hnRNP A1. Furthermore, genetic complementation analyses showed that the mutation influenced the DNA repair activity of the FANCM protein. In summary, we provide evidence for the first time showing that the common p. Arg1931* loss-of-function variant in FANCM is a risk factor for familial breast cancer.

Published
2015

158. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation

Author

Susan L. Neuhausen, Jacek Gronwald, Sofia D. Merajver, Barbara Pasini, Josephine Wagner Costalas, Andrea Eisen, Cezary Cybulski, Christine Rappaport, Noah D. Kauff, Aletta Poll, Carrie Snyder, Carey A. Cullinane, Howard M. Saal, Judy Garber, Joanne L. Blum, Albert E. Chudley, Gillian Mitchell, David M. Euhus, Gareth J.O. Evans, Stephanie A. Cohen, Barbara L. Weber, Siranoush Manoukian, Olufunmilayo I. Olopade, Mary B. Daly, Gad Rennert, Anna Jakubowska, Ophira Ginsburg, Tomasz Huzarski, Seema Panchal, Leigha Senter, John Lunn, Tuya Pal, Ellen Warner, Karen Glass, Susan Armel, Talia Donenberg, Robert E. Reilly, Jeffrey N. Weitzel, Taya Fallen, William D. Foulkes, Sonia Nanda, Pål Møller, Barry P. Rosen, Henry T. Lynch, Christian F. Singer, Eitan Friedman, Peter Ainsworth, Kenneth Offit, Dawna Gilchrist, Daniel Rayson, Charis Eng, Janice Little, Christine Elser, Louise Bordeleau, Wendy McKinnon, Susan T. Vadaparampil, Dana Zakalik, Dominique Stoppa-Lyonnet, Nadine Tung, Lovise Maehle, Ava Kwong, Jeanna McCuaig, Steven A. Narod, Marie E. Wood, Joanne Kotsopoulos, Kevin Sweet, Susan Hatters Friedman, Edmond G. Lemire, André Robidoux, Charmaine Kim-Sing, Fergus J. Couch, Tomasz Byrski, Claudine Isaacs, Beth Y. Karlan, Ping Sun, Rochelle Demsky, Jan Lubinski, Wendy S. Meschino, Raluca N. Kurz, and Kelly A. Metcalfe

Subjects
endocrine system diseases, medicine.medical_treatment, DNA Mutational Analysis, 0302 clinical medicine, Pregnancy, Risk Factors, Surveys and Questionnaires, Odds Ratio, Medicine, Insemination, Artificial, media_common, Ovarian Neoplasms, 030219 obstetrics & reproductive medicine, Obstetrics, BRCA1 Protein, Obstetrics and Gynecology, Middle Aged, female genital diseases and pregnancy complications, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Risk assessment, Infertility, Adult, medicine.medical_specialty, Reproductive Techniques, Assisted, media_common.quotation_subject, Fertility, Fertilization in Vitro, Risk Assessment, 03 medical and health sciences, Young Adult, Humans, Genetic Predisposition to Disease, Aged, Gynecology, BRCA2 Protein, In vitro fertilisation, Chi-Square Distribution, business.industry, BRCA mutation, Case-control study, Odds ratio, Fertility Agents, Female, medicine.disease, Logistic Models, Reproductive Medicine, Case-Control Studies, Multivariate Analysis, Mutation, business, Ovarian cancer
Abstract

Objective To evaluate the relationship between use of fertility medication (i.e., selective estrogen receptor [ER] modulator, gonadotropin, or other) or infertility treatment (i.e., IVF or IUI) and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Design A matched case-control study of 941 pairs of BRCA1 or BRCA2 mutation carriers with and without a diagnosis of ovarian cancer. Setting Genetic clinics. Patient(s) Detailed information regarding treatment of infertility was collected from a routinely administered questionnaire. Intervention(s) None. Main Outcome Measure(s) Conditional logistic regression was used to estimate odds ratios and 95% confidence intervals associated with fertility treatment. Result(s) There was no significant relationship between the use of any fertility medication or IVF treatment (odds ratio, 0.66; 95% confidence interval 0.18–2.33) and the subsequent risk of ovarian cancer. Conclusion(s) Our findings suggest that treatment for infertility does not significantly increase the risk of ovarian cancer among women with a BRCA mutation.

Published
2015

159. Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions

Author

Paolo Radice, G. Spatti, Siranoush Manoukian, Barbara Pasini, Maria Luisa Carcangiu, and Bernard Peissel

Subjects
Adult, Heterozygote, medicine.medical_specialty, BRCA mutations, prophylactic oophorectomy, gynecologic incidental carcinoma, endocrine system diseases, Serous carcinoma, Ovariectomy, Ubiquitin-Protein Ligases, Gastroenterology, Pathology and Forensic Medicine, Internal medicine, Ovarian carcinoma, medicine, Carcinoma, Fallopian Tube Neoplasms, Humans, Genetic Predisposition to Disease, Stage IIIC, Germ-Line Mutation, Aged, BRCA2 Protein, Ovarian Neoplasms, Gynecology, Incidental Findings, business.industry, Cancer, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, Cystadenocarcinoma, Serous, Serous fluid, medicine.anatomical_structure, Female, Surgery, Anatomy, Ovarian cancer, business, Fallopian tube
Abstract

The identification of germ-line mutations in 2 genes (BRCA1 and BRCA2) responsible for the majority of hereditary ovarian cancers has led an increasing number of women carriers of these mutations to undergo prophylactic oophorectomy (PO) to reduce their risk of subsequent ovarian carcinoma. A large number of unexpected, clinically occult neoplasms are thus being discovered. Up to December 2004, the Medical Genetics Service of the National Cancer Institute in Milan, Italy, has tested 756 probands from breast and/or ovarian cancer families for BRCA1 and BRCA2 germ-line mutations. Molecular screening of family members led to the identification of 344 female carriers of BRCA1 (239) or BRCA2 (105) germ-line mutations. Of the 186 potentially eligible women (37 of whom had tested positive for BRCA1 and 13 for BRCA2 mutation), 50 (26.8%) chose to undergo PO. Six clinically occult primary gynecologic malignancies (2 stage IIIC serous carcinomas of the ovary, 3 in situ serous carcinomas of the fallopian tube, and 1 stage IIB invasive serous carcinoma of the fallopian tube) and 1 occult ovarian metastasis from breast carcinoma were identified in the PO specimens of 7 women (all BRCA1 mutated). Four of the patients with occult primary gynecologic cancers are alive without disease 129, 87, 38, and 7 months after PO, respectively. One of the 2 patients with primary ovarian cancer and the single patient with tubal invasive carcinoma are alive with recurrent disease 83 and 20 months after PO, respectively. In addition, one of the patients whose PO specimen did not show any malignancy presented with stage IIIC tubal carcinoma 77 months after PO. The relatively high number of tubal neoplasms found at PO in this group of patients underlines the linkage between mutation and the risk of developing tubal cancer, and stresses the need to include removal of the entire tubes at the time of PO and of thoroughly evaluating the specimens at the microscopic level. The upstaging of all 3 invasive carcinomas after staging surgery, and the late recurrence and persistence of 2 of them despite treatment indicate that small size of the tumors should not preclude therapy.

Published
2006
Full Text
View/download PDF

160. Mutational screening of the RB1 gene in Italian patients with retinoblastoma reveals 11 novel mutations

Author

Alessandra Renieri, Francesca Mari, Aldo Caporossi, A. Acquaviva, Barbara Pasini, Daniela Giachino, Francesco Cetta, Maria Antonietta Mencarelli, Siranoush Manoukian, Caterina Speciale, Theodora Hadjistilianou, Katia Sampieri, Bernard Peissel, Mirella Bruttini, and Renato Frezzotti

Subjects
Male, RB1 gene, Italian population, Retinoblastoma, Mutation screening, Genetic Counseling, Biology, Settore MED/03 - GENETICA MEDICA, medicine.disease_cause, Germline, Frameshift mutation, Germline mutation, Genetics, medicine, Humans, Missense mutation, Genes, Retinoblastoma, Genetics (clinical), Base Sequence, DNA Primers, Exons, Female, Introns, Italy, Pedigree, Mutation, Settore MED/30 - MALATTIE APPARATO VISIVO, Single-strand conformation polymorphism, medicine.disease, Penetrance, eye diseases, Genes
Abstract

Retinoblastoma (RB, OMIM#180200) is the most common intraocular tumour in infancy and early childhood. Constituent mutations in the RB1 gene predispose individuals to RB development. We performed a mutational screening of the RB1 gene in Italian patients affected by RB referred to the Medical Genetics of the University of Siena. In 35 unrelated patients, we identified germline RB1 mutations in 6 out of 9 familial cases (66%) and in 7 out of 26 with no family history of RB (27%). Using the single-strand conformational polymorphism (SSCP) technique, 11 novel mutations were detected, including 3 nonsense, 5 frameshift and 4 splice-site mutations. Only two of these mutations (1 splice site and 1 missense) were previously reported. The mutation spectrum reflects the published literature, encompassing predominately nonsense or frameshift and splicing mutations. RB1 germline mutation was detected in 37% of our cases. Gross rearrangements outside the investigated region, altered DNA methylation, or mutations in non-coding regions, may be the cause of disease in the remainder of the patients. Some cases, e.g. a case of incomplete penetrance, or variable expressivity ranging from retinoma to multiple tumours, are discussed in detail. In addition, a case of pre-conception genetic counselling resolved by rescue of banked cordonal blood of the affected deceased child is described.

Published
2006
Full Text
View/download PDF

161. Classification of BRCA1 missense variants of unknown clinical significance

Author

B. Tice, B. P. M. Van Nesselrooij, Paolo Radice, David E. Goldgar, Catherine M. Phelan, Trinidad Caldés, M. De La Hoya, Åke Borg, Reyna Favis, Georgia Chenevix-Trench, V. Dapic, Elaine Kwan, kConFab, Francis Barany, Alvaro N.A. Monteiro, Siranoush Manoukian, Steven A. Narod, R. B. van der Luijt, S. Lindquist, and Sean V. Tavtigian

Subjects
Genetics, medicine.medical_specialty, endocrine system diseases, Biology, Germline mutation, Molecular genetics, medicine, Medical genetics, Missense mutation, Original Article, Clinical significance, Allele, skin and connective tissue diseases, Predictive testing, Allele frequency, Genetics (clinical)
Abstract

Background: BRCA1 is a tumour suppressor with pleiotropic actions. Germline mutations in BRCA1 are responsible for a large proportion of breast–ovarian cancer families. Several missense variants have been identified throughout the gene but because of lack of information about their impact on the function of BRCA1 , predictive testing is not always informative. Classification of missense variants into deleterious/high risk or neutral/low clinical significance is essential to identify individuals at risk. Objective: To investigate a panel of missense variants. Methods and results: The panel was investigated in a comprehensive framework that included (1) a functional assay based on transcription activation; (2) segregation analysis and a method of using incomplete pedigree data to calculate the odds of causality; (3) a method based on interspecific sequence variation. It was shown that the transcriptional activation assay could be used as a test to characterise mutations in the carboxy-terminus region of BRCA1 encompassing residues 1396–1863. Thirteen missense variants (H1402Y, L1407P, H1421Y, S1512I, M1628T, M1628V, T1685I, G1706A, T1720A, A1752P, G1788V, V1809F, and W1837R) were specifically investigated. Conclusions: While individual classification schemes for BRCA1 alleles still present limitations, a combination of several methods provides a more powerful way of identifying variants that are causally linked to a high risk of breast and ovarian cancer. The framework presented here brings these variants nearer to clinical applicability.

Published
2005
Full Text
View/download PDF

162. Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation

Author

Chiara Menin, Simona Agata, Luigi Chieco-Bianchi, Paolo Radice, G Cipollini, Laura Cortesi, Emma D'Andrea, Paolo Marchetti, Lara Della Puppa, Cristina D'Amico, Massimo Federico, Barbara Pasini, Valeria Pensotti, R. Bisegna, Silvano Presciuttini, Generoso Bevilacqua, Renato Mariani Costantini, Laura Ottini, Manuela Santarosa, M. Montagna, Sergio Ferrari, Corrado Ficorella, Davide Iandolo, Arcangela De Nicolo, C Ghimenti, Vittorio Silingardi, Paolo Aretini, Clelia de Giacomi, Daniela Turchetti, Siranoush Manoukian, Maria A. Caligo, Marco A. Pierotti, Enrico Ricevuto, Rosella Crucianelli, Fabio Marroni, Mauro Boiocchi, and Alessandra Viel

Subjects
Male, Oncology, Proband, Cancer Research, medicine.medical_specialty, Genotype, endocrine system diseases, allelic heterogeneity - BRCA1 - BRCA2 - expressivity - hereditary breast/ovarian cancer - pedigree analysis, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, cancer risk, Biology, Breast cancer, Germline mutation, Risk Factors, Internal medicine, Pancreatic cancer, medicine, Humans, BRCA1, BRCA2, genetics, Genetic Predisposition to Disease, skin and connective tissue diseases, Germ-Line Mutation, Genetics, Neoplastic, Family aggregation, medicine.disease, female genital diseases and pregnancy complications, Pedigree, Gene Expression Regulation, Neoplastic, Phenotype, Gene Expression Regulation, Genes, Italy, Male breast cancer, genetics, Female, Gene Expression Regulation, Neoplastic, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Genotype, Germ-Line Mutation, Humans, Italy, Male, Pedigree, Phenotype, Regression Analysis, Risk Factors, Regression Analysis, Female, Allelic heterogeneity, Ovarian cancer
Abstract

Mutations in BRCA1 and BRCA2 show different expressivity with respect to cancer risk, and allelic heterogeneity may be present in both genes. We collected 179 pedigrees with identified germline mutation (104 BRCA1 and 75 BRCA2), ascertained in six collaborating centers of the Italian Consortium for Hereditary Breast and Ovarian Cancer. Significant heterogeneity was detected for several variables, and a logistic regression model including age of diagnosis in the proband, presence of ovarian cancer in the family, presence of prostate or pancreatic cancer in the family, and presence of male breast cancer in the family proved to be effective in predicting the presence of a mutation in a gene rather than the other. Excess of familial aggregation of both breast and ovarian cancer was observed in both genes. Proportion of ovarian cancer was increased in the 5' portion of BRCA1, and presence of prostate or pancreatic cancer in a family was correlated with presence of ovarian cancer in BRCA2.

Published
2003
Full Text
View/download PDF

163. Rare variants in XRCC2 as breast cancer susceptibility alleles: Table 1

Author

Paul A. James, Christi J. van Asperen, Paolo Peterlongo, Alison H. Trainer, Fergus J. Couch, Paolo Radice, Fabio Capra, Javier Benitez, Jan C. Oosterwijk, Kenneth Offit, Sohela Shah, Lucia Guidugli, Xianshu Wang, Juul T. Wijnen, Javier Gracia, Florentine Hilbers, Ella R. Thompson, Siranoush Manoukian, Irene Feroce, Nicoline Hoogerbrugge, Peter Devilee, Ian G. Campbell, and Margriet Collée

Subjects
Genetics, medicine.medical_specialty, business.industry, medicine.disease, Germline, XRCC2, Breast cancer, Molecular genetics, Relative risk, Cohort, medicine, Missense mutation, Allele, skin and connective tissue diseases, business, Genetics (clinical)
Abstract

BACKGROUND Recently, rare germline variants in XRCC2 were detected in non-BRCA1/2 familial breast cancer cases, and a significant association with breast cancer was reported. However, the breast cancer risk associated with these variants needs further evaluation. METHODS The coding regions and exon-intron boundaries of XRCC2 were scanned for mutations in an international cohort of 3548 non-BRCA1/2 familial breast cancer cases and 1435 healthy controls using various mutation scanning methods. Predictions on functional relevance of detected missense variants were obtained from three different prediction algorithms. RESULTS The only protein-truncating variant detected was found in a control. Rare non-protein-truncating variants were detected in 20 familial cases (0.6%) and nine healthy controls (0.6%). Although the number of variants predicted to be damaging or neutral differed between prediction algorithms, in all instances these categories were evenly represented among cases and controls. CONCLUSIONS Our data do not confirm an association between XRCC2 variants and breast cancer risk, although a relative risk smaller than two could not be excluded. Variants in XRCC2 are unlikely to explain a substantial proportion of familial breast cancer.

Published
2012
Full Text
View/download PDF

164. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study

Author

A. Contegiacomo, Antonella Savarese, Lorenzo Preda, Laura Martincich, Luca Alessandro Carbonaro, Giovanni Di Leo, Franca Podo, Clelia de Giacomi, Rubina M. Trimboli, Filippo Santoro, Francesco Sardanelli, Matilde Pensabene, Anna Cilotti, Stefano Corcione, Siranoush Manoukian, Laura Cortesi, and Bernardo Bonanni

Subjects
Oncology, Adult, Risk, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Genes, BRCA2, Genes, BRCA1, Triple Negative Breast Neoplasms, Asymptomatic, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Contralateral Prophylactic Mastectomy, Breast cancer, Internal medicine, medicine, Mammography, Humans, Family history, Early Detection of Cancer, Aged, Gynecology, medicine.diagnostic_test, business.industry, Carcinoma, Ductal, Breast, Cancer, Middle Aged, medicine.disease, Phenotype, Treatment Outcome, 030220 oncology & carcinogenesis, Mutation, Female, medicine.symptom, business, Mastectomy, Follow-Up Studies
Abstract

Purpose: To compare phenotype features and survival of triple-negative breast cancers (TNBC) versus non-TNBCs detected during a multimodal annual screening of high-risk women. Experimental Design: Analysis of data from asymptomatic high-risk women diagnosed with invasive breast cancer during the HIBCRIT-1 study with median 9.7-year follow-up. Results: Of 501 enrolled women with BRCA1/2 mutation or strong family history (SFH), 44 were diagnosed with invasive breast cancers: 20 BRCA1 (45%), 9 BRCA2 (21%), 15 SFH (34%). Magnetic resonance imaging (MRI) sensitivity (90%) outperformed that of mammography (43%, P < 0.001) and ultrasonography (61%, P = 0.004). The 44 cases (41 screen-detected; 3 BRCA1-associated interval TNBCs) comprised 14 TNBCs (32%) and 30 non-TNBCs (68%), without significant differences for age at diagnosis, menopausal status, prophylactic oophorectomy, or previous breast cancer. Of 14 TNBC patients, 11 (79%) were BRCA1; of the 20 BRCA1 patients, 11 (55%) had TNBC; and of 15 SFH patients, 14 (93%) had non-TNBCs (P = 0.007). Invasive ductal carcinomas (IDC) were 86% for TNBCs versus 43% for non-TNBCs (P = 0.010), G3 IDCs 71% versus 23% (P = 0.006), size 16 ± 5 mm versus 12 ± 6 mm (P = 0.007). TNBC patients had more frequent ipsilateral mastectomy (79% vs. 43% for non-TNBCs, P = 0.050), contralateral prophylactic mastectomy (43% vs. 10%, P = 0.019), and adjuvant chemotherapy (100% vs. 44%, P < 0.001). The 5-year overall survival was 86% ± 9% for TNBCs versus 93% ± 5% (P = 0.946) for non-TNBCs; 5-year disease-free survival was 77% ± 12% versus 76% ± 8% (P = 0.216). Conclusions: In high-risk women, by combining an MRI-including annual screening with adequate treatment, the usual reported gap in outcome between TNBCs and non-TNBCs could be reduced. Clin Cancer Res; 22(4); 895–904. ©2015 AACR.

Published
2015

165. Constitutional de novo deletion of the FBXW7 gene in a patient with focal segmental glomerulosclerosis and multiple primitive tumors

Author

Silvia Russo, Paolo Peterlongo, Fabio Pagni, Paola Collini, Chiara Picinelli, Siranoush Manoukian, Gaia Roversi, Sara Ciceri, Bernard Peissel, Milena Crippa, Ilaria Bestetti, Daniela Perotti, Fabiana Saccheri, Pietro Luigi Poliani, Serena Catania, Palma Finelli, Roversi, G, Picinelli, C, Bestetti, I, Crippa, M, Perotti, D, Ciceri, S, Saccheri, F, Collini, P, Poliani, P, Catania, S, Peissel, B, Pagni, F, Russo, S, Peterlongo, P, Manoukian, S, and Finelli, P

Subjects
Adult, Male, F-Box-WD Repeat-Containing Protein 7, PALB2, Ubiquitin-Protein Ligases, DNA Mutational Analysis, Karyotype, Cell Cycle Proteins, Biology, Multidisciplinary, cancer, genetic, multiple primitive tumours, Malignancy, Article, Neoplasms, Multiple Primary, Focal segmental glomerulosclerosis, FBXW7, medicine, Genetic predisposition, cancer, multiple primitive tumours, Humans, Genetic Predisposition to Disease, Multiplex ligation-dependent probe amplification, Genetic Association Studies, In Situ Hybridization, Fluorescence, Comparative Genomic Hybridization, Multidisciplinary, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Glomerulosclerosis, Focal Segmental, F-Box Proteins, Wilms' tumor, Middle Aged, medicine.disease, Lymphoma, Cancer research, Female, genetic, Gene Deletion, Comparative genomic hybridization
Abstract

Multiple primary malignant neoplasms are rare entities in the clinical setting, but represent an important issue in the clinical management of patients since they could be expression of a genetic predisposition to malignancy. A high resolution genome wide array CGH led us to identify the first case of a de novo constitutional deletion confined to the FBXW7 gene, a well known tumor suppressor, in a patient with a syndromic phenotype characterized by focal segmental glomerulosclerosis and multiple primary early/atypical onset tumors, including Hodgkin’s lymphoma, Wilms tumor and breast cancer. Other genetic defects may be associated with patient’s phenotype. In this light, constitutional mutations at BRCA1, BRCA2, TP53, PALB2 and WT1 genes were excluded by performing sequencing and MLPA analysis; similarly, we ruled out constitutional abnormalities at the imprinted 11p15 region by methylation specific -MLPA assay. Our observations sustain the role of FBXW7 as cancer predisposition gene and expand the spectrum of its possible associated diseases.

Published
2015

166. Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization

Author

S. Lindstrom, Javier Benitez, Natalia Bogdanova, Christine B. Ambrosone, Judith S. Brand, Joe Dennis, Hoda Anton-Culver, Carl Blomqvist, Katarzyna Durda, Loic Le Marchand, Hiltrud Brauch, Aida Karina Dieffenbach, Veli-Matti Kosma, Heli Nevanlinna, Caroline Seynaeve, Drakoulis Yannoukakos, Gord Glendon, Stephen Burgess, Kyriaki Michailidou, Jolanta Lissowska, Thilo Dörk, Paolo Peterlongo, Helen Tsimiklis, J Lubinski, Melissa C. Southey, Robert Winqvist, Kamila Czene, Sune F. Nielsen, Anja Rudolph, Vessela N. Kristensen, Alison M. Dunning, Catherine S. Healey, Diether Lambrechts, Christi J. van Asperen, M. Rosario Alonso, C. Stegmaier, Giuseppe Floris, Per Hall, Jaana M. Hartikainen, Chun Li, Malcolm W.R. Reed, Nuria Álvarez, Anna Jakubowska, Paul D.P. Pharoah, Sara Margolin, John L. Hopper, Barbara Perkins, Francois Bacot, Michael Jones, Jacques Simard, Katarzyna Jaworska-Bieniek, Fredrick R. Schumacher, Angela Cox, Jonine D. Figueroa, Julia A. Knight, Petra Seibold, Alan Ashworth, Arja Jukkola-Vuorinen, Arif B. Ekici, Mervi Grip, Rongxi Yang, Esther M. John, Kathleen E. Malone, Vesa Kataja, Qin Wang, Fergus J. Couch, Keith Humphreys, Katja van den Hurk, Michael J. Kerin, Anna González-Neira, Jenny Chang-Claude, Daniel Vincent, Wei Zheng, Ian Tomlinson, Madeleine M. A. Tilanus-Linthorst, Ute Hamann, Amanda E. Toland, Xiao-Ou Shu, Dieter Flesch-Janys, Volker Arndt, Graham G. Giles, Rita K. Schmutzler, Julian Peto, Craig Luccarini, Børge G. Nordestgaard, Grethe I. Grenaker Alnæs, Alice S. Whittemore, Olivia Fletcher, Guillermo Pita, Matti A. Rookus, Barbara Burwinkel, Lothar Haeberle, Hermann Brenner, John W. M. Martens, Mitul Shah, Marilie D. Gammon, Patrick Neven, Emilie Cordina-Duverger, Jose Ignacio Arias Perez, Ben Zhang, Martine Dumont, Mel Maranian, Annika Lindblom, Habibul Ahsan, Susan L. Neuhausen, Mikael Eriksson, Jingmei Li, Carmel Apicella, Frederik Marmé, Peter Kraft, Hatef Darabi, Ulrike Peters, Hans Wildiers, Arto Mannermaa, J. Margriet Collée, Pascal Guénel, Peter Devilee, M.J. Hooning, Daniel C. Tessier, Shahana Ahmed, Paolo Radice, Montserrat Garcia-Closas, Elinor J. Sawyer, Louise A. Brinton, Susan L. Slager, Bernardo Bonanni, Peter A. Fasching, Simon S. Cross, Thérèse Truong, Matthias W. Beckmann, Catriona McLean, Douglas F. Easton, Georgia Chenevix-Trench, David J. Hunter, Kristiina Aittomäki, Janet E. Olson, Henrik Flyger, Chenjie Zeng, Nick Orr, Siranoush Manoukian, Antonenkova Nn, Stig E. Bojesen, Wan-Qing Wen, Jirong Long, Nicola Miller, Brandon L. Pierce, Ryan J. Delahanty, Anthony J. Swerdlow, Brian E. Henderson, Harald Surowy, Yon-Dschun Ko, Celine M. Vachon, Daniel Herrero, Christopher A. Haiman, Sandrine Tchatchou, Florence Menegaux, Katri Pylkäs, Taru A. Muranen, Roger L. Milne, Thomas Brüning, Marjanka K. Schmidt, Manjeet K. Bolla, M. Pilar Zamora, Irene L. Andrulis, Caroline Baynes, Emily Hallberg, D. Seminara, Isabel dos-Santos-Silva, Diana Torres, Wim L. A. M. de Kort, Nichola Johnson, Public and occupational health, Clinical Genetics, Virology, Medical Oncology, Surgery, and Landsteiner Laboratory

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Pathology, coronary-artery-disease, prospective cohort, Genome-wide association study, Breast Neoplasms, Article, different anatomic sites, Breast cancer, SDG 3 - Good Health and Well-being, Risk Factors, Internal medicine, common variants, Mendelian randomization, Odds Ratio, Medicine, Humans, Prospective Studies, Risk factor, Prospective cohort study, Evidence-Based Medicine, business.industry, body-fat distribution, Mendelian Randomization Analysis, multiple genetic-variants, Odds ratio, medicine.disease, susceptibility loci, Body Height, interleukin-6 receptor, adult human height, Relative risk, genome-wide association, Female, business
Abstract

Background: Epidemiological studies have linked adult height with breast cancer risk in women. However, the magnitude of the association, particularly by subtypes of breast cancer, has not been established. Furthermore, the mechanisms of the association remain unclear. Methods: We performed a meta-analysis to investigate associations between height and breast cancer risk using data from 159 prospective cohorts totaling 5 216 302 women, including 113 178 events. In a consortium with individual-level data from 46 325 case patients and 42 482 control subjects, we conducted a Mendelian randomization analysis using a genetic score that comprised 168 height-associated variants as an instrument. This association was further evaluated in a second consortium using summary statistics data from 16 003 case patients and 41 335 control subjects. Results: The pooled relative risk of breast cancer was 1.17 (95% confidence interval [CI] = 1.15 to 1.19) per 10 cm increase in height in the meta-analysis of prospective studies. In Mendelian randomization analysis, the odds ratio of breast cancer per 10 cm increase in genetically predicted height was 1.22 (95% CI = 1.13 to 1.32) in the first consortium and 1.21 (95% CI = 1.05 to 1.39) in the second consortium. The association was found in both premenopausal and postmenopausal women but restricted to hormone receptor-positive breast cancer. Analyses of height-associated variants identified eight new loci associated with breast cancer risk after adjusting for multiple comparisons, including three loci at 1q21.2, DNAJC27, and CCDC91 at genome-wide significance level P < 5 × 10-8. Conclusions: Our study provides strong evidence that adult height is a risk factor for breast cancer in women and certain genetic factors and biological pathways affecting adult height have an important role in the etiology of breast cancer.

Published
2015
Full Text
View/download PDF

167. Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy

Author

Virginia Valentini, Monica Barile, Marco Montagna, Simonetta Bianchi, Piera Rizzolo, Giovanna Masala, Laura Cortesi, Giovanni Chillemi, Veronica Zelli, Stefania Tommasi, Alessandra Viel, Paolo Peterlongo, Domenico Palli, Siranoush Manoukian, Laura Ottini, Liliana Varesco, Valentina Silvestri, Calogero Saieva, Giuseppe Giannini, Ines Zanna, Antonio Russo, Paolo Radice, Marco Scarnò, Valeria Pensotti, Anna Sara Navazio, Silvestri, V., Rizzolo, P., Scarnã², M., Chillemi, G., Navazio, A., Valentini, V., Zelli, V., Zanna, I., Saieva, C., Masala, G., Bianchi, S., Manoukian, S., Barile, M., Pensotti, V., Peterlongo, P., Varesco, L., Tommasi, S., Russo, A., Giannini, G., Cortesi, L., Viel, A., Montagna, M., Radice, P., Palli, D., and Ottini, L.

Subjects
Male, Cancer Research, Predictive Value of Test, 8q24.21, BRCA1/2, Clinical-pathologic characteristics, Low-penetrance BC alleles, Male breast cancer, SNPs, BRCA1 Protein, BRCA2 Protein, Biomarkers, Tumor, Breast Neoplasms, Male, Case-Control Studies, Chi-Square Distribution, Gene Frequency, Genetic Predisposition to Disease, Heterozygote, Homozygote, Humans, Italy, Linear Models, Logistic Models, Multivariate Analysis, Mutation, Odds Ratio, Phenotype, Predictive Value of Tests, Risk Factors, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 8, Chromosomes, Human, Pair 9, Polymorphism, Single Nucleotide, Oncology, Genotype, Medicine, skin and connective tissue diseases, Multivariate Analysi, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Genetics, Clinical-pathologic characteristic, Linear Model, Case-Control Studie, Human, Logistic Model, SNP, Single-nucleotide polymorphism, Breast cancer, Allele frequency, business.industry, Risk Factor, Case-control study, Odds ratio, medicine.disease, business, Low-penetrance BC allele
Abstract

Increasing evidence indicates that common genetic variants may contribute to the heritable risk of breast cancer (BC). In this study, we investigated whether single nucleotide polymorphisms (SNPs), within the 8q24.21 multi-cancer susceptibility region and within BC-associated loci widespread in the genome, may influence the risk of BC in men, and whether they may be associated with specific clinical-pathologic characteristics of male BC (MBC). In the frame of the ongoing Italian Multicenter Study on MBC, we performed a case-control study on 386 MBC cases, including 50 BRCA1/2 mutation carriers, and 1105 healthy male controls, including 197 unaffected BRCA1/2 mutation carriers. All 1491 subjects were genotyped by Sequenom iPLEX technology for a total of 29 susceptibility SNPs. By logistic regression models, we found a significant association with MBC risk for five SNPs: rs1562430 (p = 0.002) and rs445114 (p = 0.026) both within the 8q24.21 region; rs1011970/9p21.3 (p = 0.011), rs614367/11q13.3 (p = 0.016) and rs1314913/14q24.1 (p < 0.0001). Differences in the distribution of rs614367/11q13.3 genotypes according to oestrogen receptor (ER) status (p = 0.006), and of rs1011970/9p21.3 genotypes according to human epidermal growth factor receptor 2 (HER2) status (p = 0.002) emerged. Association of rs1011970/9p21.3 risk genotype with HER2+ MBC was confirmed by a multivariate analysis. rs1314913/14q24.1 was associated with increased MBC risk in analyses restricted to male BRCA1/2 mutation carriers (p = 0.041). In conclusion, we provided the first evidence that the 8q24.21 region is associated with MBC risk. Furthermore, we showed that the SNPs rs1562430/8q24.21 and rs1314913/14q24.1 strongly influence BC risk in men and suggested that the SNP rs1314913/14q24.1 may act as a risk modifier locus in male BRCA1/2 mutation carriers.

Published
2015

168. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

Author

Rongxi Yang, Hoda Anton-Culver, Dieter Flesch-Janys, Veli-Matti Kosma, Alexander Miron, Siranoush Manoukian, Giulietta Scuvera, Sten Cornelissen, Fergus J. Couch, Beth Y. Karlan, Janet E. Olson, Katarzyna Durda, Muhammad Usman Rashid, Diana Eccles, Debra Frost, Antonis C. Antoniou, William J. Tapper, José Ignacio Arias, Madeleine M. A. Tilanus-Linthorst, Ute Hamann, Sara Margolin, Thilo Dörk, Pilar Zamora, Sune F. Nielsen, Laura Papi, Radka Platte, Fabio Capra, Marjanka K. Schmidt, Matthias W. Beckmann, Peter A. Fasching, Tjoung Won Park-Simon, Lesley McGuffog, Alfons Meindl, Amanda B. Spurdle, Barbara Wappenschmidt, Katherine L. Nathanson, Bernardo Bonanni, Christine L. Clarke, Julian Adlard, Fiona M. Blows, Arja Jukkola-Vuorinen, Isabel dos-Santos-Silva, Catriona McLean, Georgia Chenevix-Trench, Frederique Mariette, Malcolm W.R. Reed, Douglas F. Easton, Vesa Kataja, Frederik Marmé, Laura Baglietto, Christopher A. Haiman, Monica Barile, Uffe Birk Jensen, Thomas Brüning, Shan Wang-Gohrke, Thomas Rüdiger, Paolo Radice, Alessandra Viel, Annegien Broeks, Dee W. West, Loic Le Marchand, Mary Beth Terry, Jenny Chang-Claude, Lorraine Durcan, Raymonda Varon-Mateeva, Brian E. Henderson, Robert A.E.M. Tollenaar, Hansjoerg Plendl, Katri Pylkäs, Jane Carpenter, Mads Thomassen, Kenneth Offitt, Sabine Preisler-Adams, Dennis J. Slamon, Kamila Czene, D. Gareth Evans, Senno Verhoef, Jonine Figueroa, Anja Rudolph, Kristiina Aittomäki, Arto Mannermaa, Eric Hahnen, Jacek Gronwald, Aida Karina Dieffenbach, Johanna Rantala, Ruth Swann, Paolo Peterlongo, Melissa C. Southey, Liliana Varesco, Katarzyna Jaworska-Bieniek, Elena Provenzano, Henrik Flyger, Hiltrud Brauch, Trevor Cole, Alison M. Dunning, Sue Healey, Robert Winqvist, Soo Hwang Teo, Rachel E. Factor, Timothy R. Rebbeck, Jaana M. Hartikainen, Irene L. Andrulis, Louise Jones, Rosemary L. Balleine, Gord Glendon, Doris Steinemann, David E. Goldgar, Anna Jakubowska, Paul D.P. Pharoah, Miriam Dwek, Heli Nevanlinna, Karin Kast, Nichola Johnson, Stefano Fortuzzi, Argyrios Ziogas, John W.M. Martens, Christa Stegmaier, Vernon S. Pankratz, Peter Devilee, Thomas Hansen, Christian Sutter, Vijai Joseph, Ana Osorio, Harald Surovy, Päivi Heikkilä, Kerstin Rhiem, Fredrick R. Schumacher, Susan L. Neuhausen, Michael T. Parsons, Jolanta Lissowska, Stig E. Bojesen, Jo Perkins, Christi J. van Asperen, Simon S. Cross, Susan M. Domchek, Alice S. Whittemore, J. Margriet Collée, Trinidad Caldés, Rosemarie Davidson, Judy Garber, Nina Ditsch, Norbert Arnold, Annika Lindblom, Taru A. Muranen, Rodney J. Scott, Hans Ulrich Ulmer, Åke Borg, Qin Wang, V. Arndt, Christoph Engel, Hermann Brenner, Esther M. John, Rita K. Schmutzler, Julian Peto, Jan Lubinski, Børge G. Nordestgaard, Diana Torres, Barbara Burwinkel, Natalia Bogdanova, Caroline Seynaeve, Steve Ellis, Per Hall, Daniela Zaffaroni, Peter Hillemanns, Yon Ko, Mark E. Robson, Arif B. Ekici, Roger L. Milne, Nadine Tung, Petra Seibold, Marco Montagna, Stephen J. Chanock, Louise Izatt, Andrew K. Godwin, Mervi Grip, Rohini Rau-Murthy, Anna González-Neira, Amanda E. Toland, Anna Marie Mulligan, Noralane M. Lindor, Daniel Barrowdale, Louise A. Brinton, Olivia Fletcher, Anita Bane, Dieter Niederacher, Angela Cox, Maartje J. Hooning, Barbara Pasini, Manjeet K. Bolla, Carl Blomqvist, Ros Eeles, Graham G. Giles, and Javier Benitez

Subjects
Oncology, Pathology, Cancer Research, endocrine system diseases, Receptor, ErbB-2, Genes, BRCA2, Genes, BRCA1, Triple Negative Breast Neoplasms, Tumor Status, ErbB-2, Medizinische Fakultät, Receptors, 10. No inequality, skin and connective tissue diseases, Progesterone, Medicine(all), Likelihood Functions, Age Factors, Middle Aged, Adult, Aged, Breast Neoplasms, Carcinoma, Female, Humans, Mutation, Neoplasm Grading, Neoplasm Staging, Receptors, Estrogen, Receptors, Progesterone, 3. Good health, Mutation (genetic algorithm), Receptor, Research Article, medicine.medical_specialty, Breast cancer, Germline mutation, Internal medicine, medicine, Clinical significance, ddc:610, business.industry, Cancer, medicine.disease, BRCA1, Estrogen, BRCA2, BRCA2 Mutation Carrier, Genes, Mutation testing, business
Abstract

Introduction The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation. Histopathological features thus have utility for mutation prediction, including statistical modeling to assess pathogenicity of BRCA1 or BRCA2 variants of uncertain clinical significance. We analyzed large pathology datasets accrued by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC) to reassess histopathological predictors of BRCA1 and BRCA2 mutation status, and provide robust likelihood ratio (LR) estimates for statistical modeling. Methods Selection criteria for study/center inclusion were estrogen receptor (ER) status or grade data available for invasive breast cancer diagnosed younger than 70 years. The dataset included 4,477 BRCA1 mutation carriers, 2,565 BRCA2 mutation carriers, and 47,565 BCAC breast cancer cases. Country-stratified estimates of the likelihood of mutation status by histopathological markers were derived using a Mantel-Haenszel approach. Results ER-positive phenotype negatively predicted BRCA1 mutation status, irrespective of grade (LRs from 0.08 to 0.90). ER-negative grade 3 histopathology was more predictive of positive BRCA1 mutation status in women 50 years or older (LR = 4.13 (3.70 to 4.62)) versus younger than 50 years (LR = 3.16 (2.96 to 3.37)). For BRCA2, ER-positive grade 3 phenotype modestly predicted positive mutation status irrespective of age (LR = 1.7-fold), whereas ER-negative grade 3 features modestly predicted positive mutation status at 50 years or older (LR = 1.54 (1.27 to 1.88)). Triple-negative tumor status was highly predictive of BRCA1 mutation status for women younger than 50 years (LR = 3.73 (3.43 to 4.05)) and 50 years or older (LR = 4.41 (3.86 to 5.04)), and modestly predictive of positive BRCA2 mutation status in women 50 years or older (LR = 1.79 (1.42 to 2.24)). Conclusions These results refine likelihood-ratio estimates for predicting BRCA1 and BRCA2 mutation status by using commonly measured histopathological features. Age at diagnosis is an important variable for most analyses, and grade is more informative than ER status for BRCA2 mutation carrier prediction. The estimates will improve BRCA1 and BRCA2 variant classification and inform patient mutation testing and clinical management. Electronic supplementary material The online version of this article (doi:10.1186/s13058-014-0474-y) contains supplementary material, which is available to authorized users.

Published
2014
Full Text
View/download PDF

169. Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy

Author

L. Varesco, Calogero Saieva, Giovanna Masala, Piera Rizzolo, Stefania Tommasi, Antonio Russo, Paolo Peterlongo, Ines Zanna, Siranoush Manoukian, Ma Caligo, Carlo Capalbo, Laura Ottini, Paolo Radice, Mario Falchetti, Marco Montagna, Giulia Cini, Domenico Palli, Valentina Silvestri, Giuseppe Giannini, Laura Cortesi, M. Barile, Anna Sara Navazio, Simonetta Bianchi, Ottini, L., Rizzolo, P., Zanna, I., Silvestri, V., Saieva, C., Falchetti, M., Masala, G., Navazio, A.S., Capalbo, C., Bianchi, S., Manoukian, S., Barile, M., Peterlongo, P., Caligo, M.A., Varesco, L., Tommasi, S., Russo, A., Giannini, G., Cortesi, L., Cini, G., Montagna, M., Radice, P., and Palli, D.

Subjects
Oncology, Asian Continental Ancestry Group, Male, medicine.medical_specialty, Cancer Research, Genotype, medicine.drug_class, Receptor, ErbB-2, Settore MED/06 - Oncologia Medica, Estrogen receptor, Genetic Association Studie, Biology, Hyperestrogenism, Polymorphism, Single Nucleotide, Breast Neoplasms, Male, Breast cancer, Gene Frequency, Internal medicine, Sulfotransferase 1A1 (SULT1A1), Genetic variation, medicine, Genetic Predisposition to Disease, Allele, skin and connective tissue diseases, Risk Factor, Middle Aged, medicine.disease, Estrogen, Arylsulfotransferase, Male breast cancer, Gene Expression Regulation, Neoplastic, Endocrinology, SULT1A1 Arg213His polymorphism, Italy, medicine.symptom, Human
Abstract

Male breast cancer (MBC) is rare and poorly understood. Like female breast cancer (FBC), MBCs are highly sensitive to hormonal changes, and hyperestrogenism, specifically, represents a major risk factor for MBC. MBC is considered similar to late-onset, post-menopausal estrogen/progesteron receptors positive FBC (ER+/PR+). Sulfotransferase 1A1 (SULT1A1) is an enzyme involved in the metabolism of estrogens. Recently, SULT1A1 common functional polymorphism Arg213His (638G>A) variant has been found to be associated with increased breast cancer (BC) risk, particularly in post-menopausal women. For this reason, we decided to explore whether SULT1A1 Arg213His could exert an effect on MBC development. The primary aim of this study was to evaluate the influence of the SULT1A1 Arg213His polymorphism on MBC risk. The secondary aim was to investigate possible associations with relevant clinical–pathologic features of MBC. A total of 394 MBC cases and 786 healthy male controls were genotyped for SULT1A1 Arg213His polymorphism by PCR–RFLP and high-resolution melting analysis. All MBC cases were characterized for relevant clinical–pathologic features. A significant difference in the distribution of SULT1A1 Arg213His genotypes was found between MBC cases and controls (P

Published
2014

170. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1

Author

Paolo Radice, Mohosin Sarkar, Claudia Foglia, Laura Caleca, Monica Barile, Caterina Congregati, Carla B. Ripamonti, Loris Bernard, Daniela Zaffaroni, Anna Laura Putignano, Siranoush Manoukian, Thomas J. Magliery, Laura Papi, Mara Colombo, Carlo Tondini, Valeria Pensotti, and Bernard Peissel

Subjects
Mutation rate, Heredity, lcsh:Medicine, Mutation Rate, Chromosome Segregation, Breast Tumors, Protein Isoforms, Coding region, lcsh:Science, Ovarian Neoplasms, Genetics, education.field_of_study, Multidisciplinary, Geography, BRCA1 Protein, Cancer Risk Factors, Age Factors, Obstetrics and Gynecology, Exons, Middle Aged, Founder Effect, Ovarian Cancer, Gene Expression Regulation, Neoplastic, Italy, Oncology, Mutation (genetic algorithm), Medicine, Female, RING Finger Domains, Protein Binding, Research Article, Adult, Cancer-Predisposing Gene, Ubiquitin-Protein Ligases, Green Fluorescent Proteins, Population, Breast Neoplasms, Biology, Molecular Genetics, Genetic Mutation, BARD1, Breast Cancer, Cancer Genetics, Humans, Family, Genetic Predisposition to Disease, RNA, Messenger, education, Tumor Suppressor Proteins, Haplotype, lcsh:R, Cancers and Neoplasms, Human Genetics, BRCA1, Molecular biology, Haplotypes, Mutation, Genetics of Disease, lcsh:Q, Gynecological Tumors, Founder effect
Abstract

The identification of founder mutations in cancer predisposing genes is important to improve risk assessment in geographically defined populations, since it may provide specific targets resulting in cost-effective genetic testing. Here, we report the characterization of the BRCA1 c.190T>C (p.Cys64Arg) mutation, mapped to the RING-finger domain coding region, that we detected in 43 hereditary breast/ovarian cancer (HBOC) families, for the large part originating from the province of Bergamo (Northern Italy). Haplotype analysis was performed in 21 families, and led to the identification of a shared haplotype extending over three BRCA1-associated marker loci (0.4 cM). Using the DMLE+2.2 software program and regional population demographic data, we were able to estimate the age of the mutation to vary between 3,100 and 3,350 years old. Functional characterization of the mutation was carried out at both transcript and protein level. Reverse transcriptase-PCR analysis on lymphoblastoid cells revealed expression of full length mRNA from the mutant allele. A green fluorescent protein (GFP)-fragment reassembly assay showed that the p.Cys64Arg substitution prevents the binding of the BRCA1 protein to the interacting protein BARD1, in a similar way as proven deleterious mutations in the RING-domain. Overall, 55 of 83 (66%) female mutation carriers had a diagnosis of breast and/or ovarian cancer. Our observations indicate that the BRCA1 c.190T>C is a pathogenic founder mutation present in the Italian population. Further analyses will evaluate whether screening for this mutation can be suggested as an effective strategy for the rapid identification of at-risk individuals in the Bergamo area.

Published
2014

171. FGF receptor genes and breast cancer susceptibility: Results from the Breast Cancer Association Consortium

Author

Arif B. Ekici, Betül T. Yesilyurt, Wei-Yen Lim, Xiao-Ou Shu, Xianshu Wang, Heli Nevanlinna, Katarzyna Jaworska-Bieniek, José Ignacio Arias-Perez, Jenny Chang-Claude, Miao Hui, Hiroji Iwata, Giuseppe Floris, Diether Lambrechts, Graham G. Giles, Leticia Tais Moreno, Chen-Yang Shen, Suleeporn Sangrajrang, Paolo Peterlongo, Malcolm W.R. Reed, Jesús Herranz, F Marmé, Melissa C. Southey, James McKay, H. Flyer, Sook Ryun Park, Dong-Young Noh, Jolanta Lissowska, Jan Lubinski, Alison M. Dunning, Robert Winqvist, Kerstin B. Meyer, Keitaro Matsuo, Stig E. Bojesen, Pascal Guénel, Kavitta Sivanandan, Vesa Kataja, Peter Devilee, Qiuyin Cai, Anna Jakubowska, Paul D.P. Pharoah, Roger L. Milne, Fergus J. Couch, Kenneth Muir, Hidemi Ito, Katarzyna Durda, Georgia Chenevix-Trench, Frederique Mariette, Taru A. Muranen, Qin Wang, Pornthep Siriwanarangsan, Sara Margolin, Manjeet K. Bolla, Daniel F. Schmidt, Celine M. Vachon, Carl Blomqvist, M Garcia-Closas, Claire Mulot, Paolo Radice, Fredrick R. Schumacher, Madeleine M. A. Tilanus-Linthorst, Ute Hamann, Mitul Shah, Matthias W. Beckmann, J. M. Collee, Wei Zheng, Philip Iau, Marta Mendiola, Christopher A. Haiman, Mikael Hartman, Hiltrud Brauch, Chiu-Chen Tseng, Dieter Flesch-Janys, F. Labrèche, Javier Benitez, Laura Baglietto, N. Kondo, Michael J. Kerin, Mikael Eriksson, Nicola Miller, Janet E. Olson, Jirong Long, Kristiina Aittomäki, Mark S. Goldberg, Daniel O. Stram, Wan Ting Tay, Artitaya Lophatananon, S. Tchatchou, Guillermo Pita, Loic Le Marchand, Katri Pylkäs, Natalia Bogdanova, Arja Jukkola-Vuorinen, Wei Lu, L.J. van 't Veer, Peter A. Fasching, P. Zamora, Anja Rudolph, Stefan P. Renner, Karin Leunen, Angela Cox, Drakoulis Yannoukakos, Arto Mannermaa, Ian W. Brock, William J. Blot, Nick Orr, Yu Tang Gao, Kristen S. Purrington, Jacques Simard, Maartje J. Hooning, Anthony J. Swerdlow, Siranoush Manoukian, Irene L. Andrulis, David Hardisson, Nichola Johnson, Martine Dumont, Primitiva Menendez-Rodriguez, R.A.E.M. Tollenaar, Veli-Matti Kosma, Gianluca Severi, Aida Karina Dieffenbach, Volker Arndt, Silvia Pineda, Annika Lindblom, D. J. Van Den Berg, Stephen J. Chanock, Cheng Har Yip, Hermann Brenner, Chia-Ni Hsiung, MaryPat Jones, Thomas Brüning, Enes Makalic, Hatef Darabi, Mervi Grip, I dos Santos Silva, J. C. Yu, Sandra Deming-Halverson, Mieke Kriege, Soo Hwang Teo, Gordon Glendon, Julian Peto, Kamila Czene, Annegien Broeks, C. Stegmaier, Børge G. Nordestgaard, Barbara Burwinkel, María R Alonso, John L. Hopper, Joe Dennis, Jun Li, Thilo Dörk, Efraim H. Rosenberg, Divyansh Agarwal, Bing Zhang, Caroline Seynaeve, Jaana M. Hartikainen, Anna González-Neira, Ian Tomlinson, Thérèse Truong, Amanda E. Toland, María José Sánchez, Anna H. Wu, Douglas F. Easton, Olivia Fletcher, M-F. Hou, B. E. Henderson, Daehee Kang, Jung Yun Choi, Keith Humphreys, Kyriaki Michailidou, Sarah Stewart-Brown, Per Hall, Elinor J. Sawyer, Marjanka K. Schmidt, Jonine D. Figueroa, Julia A. Knight, Petra Seibold, Alan Ashworth, Martha J. Shrubsole, Clinical Genetics, Cardiothoracic Surgery, Medical Oncology, Surgery, and Erasmus MC other

Subjects
Cancer Research, Fibroblast Growth Factor, Genome-wide association study, disease subtypes, Bioinformatics, susceptibility, Genotype, single-nucleotide polymorphisms, common variants, risk, Research Support, Non-U.S. Gov't, identifies 2, Single Nucleotide, 3. Good health, Multicenter Study, ovarian-cancer, Type 5, Oncology, loci, alleles, Female, Type 4, Type 3, Type 2, Receptor, Type 1, SNP, Single-nucleotide polymorphism, Breast Neoplasms, Biology, Polymorphism, Single Nucleotide, RC0254, Case-Control Studies, Genetic Variation, Genome-Wide Association Study, Humans, Receptor, Fibroblast Growth Factor, Type 1, Receptor, Fibroblast Growth Factor, Type 2, Receptor, Fibroblast Growth Factor, Type 3, Receptor, Fibroblast Growth Factor, Type 4, Receptor, Fibroblast Growth Factor, Type 5, Genetic Predisposition to Disease, Breast cancer, breast cancer, Research Support, N.I.H., Extramural, SDG 3 - Good Health and Well-being, medicine, Journal Article, Polymorphism, QH426, Genetic association, brca2 mutations, Case-control study, Genetics and Genomics, Odds ratio, medicine.disease, confer susceptibility, FGF receptors, genome-wide association, Ovarian cancer, Research Support, U.S. Gov't, Non-P.H.S
Abstract

Background:Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium.\ud \ud Methods:Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression.\ud \ud Results:Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95 confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2.\ud \ud Conclusion:Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2. © 2014 Cancer Research UK.

Published
2014
Full Text
View/download PDF

172. PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo

Author

Monica Barile, Paolo Peterlongo, Mara Colombo, Anna Falanga, Chiara Corna, Paolo Radice, Fernando Ravagnani, Tiziana Bianchi, Domenico Sardella, Irene Catucci, Sara Ciceri, Paolo Verderio, Bernard Peissel, Graziella Pasquini, Giulietta Scuvera, Laura Galastri, Stefano Fortuzzi, Bernardo Bonanni, Claudia Foglia, Sara Pizzamiglio, Siranoush Manoukian, Loris Bernard, Carlo Tondini, Marina Marchetti, Catucci, I, Peterlongo, P, Ciceri, S, Colombo, M, Pasquini, G, Barile, M, Bonanni, B, Verderio, P, Pizzamiglio, S, Foglia, C, Falanga, A, Marchetti, M, Galastri, L, Bianchi, T, Corna, C, Ravagnani, F, Bernard, L, Fortuzzi, S, Sardella, D, Scuvera, G, Peissel, B, Manoukian, S, and Tondini, C

Subjects
Oncology, medicine.medical_specialty, Genotype, PALB2, DNA Mutational Analysis, Breast Neoplasms, White People, breast cancer, Internal medicine, Medicine, Humans, Recurrent mutation, Genetic Predisposition to Disease, skin and connective tissue diseases, Genetics (clinical), Alleles, Polymorphism, Genetic, business.industry, Tumor Suppressor Proteins, Nuclear Proteins, Italy, Case-Control Studies, Mutation (genetic algorithm), Mutation, Female, Familial breast cancer, business, Fanconi Anemia Complementation Group N Protein
Abstract

Purpose:Monoallelic germ-line deleterious mutations of PALB2 (partner and localizer of BRCA2) are associated with breast cancer risk and have been found in several populations, with carrier frequencies of ∼1-2%. Initially, these mutations were considered to have moderate penetrance, but accumulating evidence now indicates that they are associated with much higher risk.Methods:In this study, we sequenced the PALB2 coding regions unlinked to BRCA (breast cancer) genes in 575 probands from Italian breast cancer families recruited in Milan.Results:We found 12 carriers (2.1%) of deleterious mutations, and none of the mutations was found in 784 controls collected in Milan. One of these mutations, the c.1027C>T (p.Gln343X), was found to be recurrent in the province of Bergamo in northern Italy, being detected in 6/113 (5.3%) familial breast cancer cases and 2/477 (0.4%) controls recruited in this area (Fisher's exact test: P < 0.01).Conclusions:Our data provide confirmatory findings that, in the Italian population also, deleterious mutations of PALB2 are relatively frequent predisposing factors for breast cancer and may be associated with high risk of the disease.Genet Med 16 9, 688-694.

Published
2013

173. Characterization of a cytogenetic 17q11.2 deletion in an NF1 patient with a contiguous gene syndrome

Author

Luisa Doneda, Paola Riva, Siranoush Manoukian, Giuseppe Marini, Johannes Den Dunnen, Lidia Larizza, Leda Dalprà, and Pierangela Castorina

Subjects
Adult, Male, Yeast artificial chromosome, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Neurofibromatosis 1, Locus (genetics), Biology, Contiguous gene syndrome, Gene mapping, Genes, Neurofibromatosis 1, Genetics, medicine, Humans, Child, neoplasms, Alleles, In Situ Hybridization, Fluorescence, Genetics (clinical), medicine.diagnostic_test, Intron, Cytogenetics, Chromosome Mapping, medicine.disease, nervous system diseases, Karyotyping, Microsatellite, Female, Gene Deletion, Polymorphism, Restriction Fragment Length, Chromosomes, Human, Pair 17, Fluorescence in situ hybridization
Abstract

We report on a rare patient screened as a putative carrier of a contiguous gene syndrome on the basis of a complex phenotype characterized by sporadic neurofibromatosis type 1 (NF1), dysmorphism, mental retardation and severe skeletal anomalies. A cytogenetically visible 17q11.2 deletion was detected in the patient’s karyotype by high-resolution banding and confirmed by fluorescence in situ hybridization with yeast artificial chromosomes targeting the NF1 region. Analysis of the segregation from parents to proband of 13 polymorphic DNA markers, either contiguous or contained within the NF1 gene, showed that the patient is hemizygous at sites within the NF1 gene – the AAAT-Alu repeat in the 5′ region of intron 27b, the CA/GT microsatellite in the 3′ region of intron 27b, and the CA/GT microsatellite in intron 38 – and at the extragenic D17S798 locus, distal to the 3′ end of NF1. The patient may be an important resource in the identification of genes downstream of NF1 that may contribute to some of his extra-NF1 clinical signs.

Published
1996
Full Text
View/download PDF

174. Cardio-facio-cutaneous (CFC) syndrome: Report of an adult without mental retardation

Author

Angelo Selicorni, Giovanni Neri, Siranoush Manoukian, R. Cavalli, Faustina Lalatta, and Gianluca Tadini

Subjects
Adult, medicine.medical_specialty, Genetic inheritance, integumentary system, business.industry, Woolly hair, Cardio facio cutaneous, Dermatology, Craniofacial Abnormalities, Infundibular pulmonic stenosis, Face, Intellectual Disability, cardiovascular system, Humans, Patchy alopecia, Medicine, Abnormalities, Multiple, Female, cardiovascular diseases, CFC SYNDROME, Young adult, Hair Diseases, business, Genetics (clinical), Scant body hair
Abstract

We report on a 25-year-old woman with typical manifestations of the cardio-facio-cutaneous (CFC) syndrome, but without mental retardation. She had valvular and infundibular pulmonic stenosis, brittle and woolly hair with patchy alopecia, scant body hair, dry and hypohydrotic skin, and characteristic facial traits. To our knowledge, this is the first case of CFC syndrome without mental retardation but typical cutaneous findings.

Published
1996
Full Text
View/download PDF

176. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

Author

Michael Lush, Hans Wildiers, Christopher A. Haiman, Nils Schoof, Per Hall, Beatrice Melin, Hiltrud Brauch, Liisa M. Pelttari, Angela Brooks-Wilson, Laima Tihomirova, Ingo B. Runnebaum, Hui Cai, Kenneth Offit, Michael P. Lux, Robert Edwards, Julia A. Knight, Ignace Vergote, Arto Leminen, Alan Ashworth, Kyriaki Michailidou, Martha J. Shrubsole, Sophie Giraud, Nadeem Siddiqui, Katri Pylkäs, Sune F. Nielsen, Vernon S. Pankratz, Lenka Foretova, Anna González-Neira, Ian Tomlinson, Thérèse Truong, Anna Marie Mulligan, Andreas du Bois, Christi J. van Asperen, Nuria Álvarez, M. Pilar Zamora, Theo A. Mvan Os, Susan J. Ramus, Olivia Fletcher, Usha Menon, Olivier Caron, Dieter Flesch-Janys, Sara H. Olson, Ellen L. Goode, Yael Laitman, Jingmei Li, Lynne R. Wilkens, Carmel Apicella, Brooke L. Fridley, Robert Luben, Mark S. Goldberg, Mary Anne Rossing, Dominique Stoppa-Lyonnet, Jonathan Beesley, Jan Lubinski, Paolo Peterlongo, Phuong L. Mai, Henrik Flyger, Thilo Dörk, Douglas A. Levine, Rob B. van der Luijt, Stig E. Bojesen, Javier Benitez, Natalia Bogdanova, Stephen J. Chanock, Andrew K. Godwin, Sharon E. Johnatty, Helga B. Salvesen, Juliet D. French, Daphne Gschwantler Kaulich, Rod Karevan, Arif B. Ekici, Marc Frenay, Taru A. Muranen, Jirong Long, Catherine S. Healey, Craig Luccarini, Chen-Yang Shen, Lorna Gibson, Pascal Guénel, Hidemi Ito, Nicholas T. Woods, Drakoulis Yannoukakos, Thomas Hansen, Francesca Damiola, Valérie Bonadona, Satoyo Hosono, Marion Piedmonte, Steve Ellis, Suleeporn Sangrajrang, Aleksandra Gentry-Maharaj, James McKay, Olga M. Sinilnikova, Jennifer A. Doherty, Xiao-Ou Shu, Curtis Olswold, Nhu D. Le, Michael J. Kerin, Malcolm C. Pike, Jenny Chang-Claude, Gianluca Severi, Michael Jones, Linda E. Kelemen, Loic Le Marchand, Maureen E. Hoatlin, Fredrick R. Schumacher, Dieter Niederacher, Michael E. Carney, Angela Cox, Attila Teoman, Hannah P. Yang, Graham G. Giles, Jianjun Liu, Xiaoqing Chen, Elisa V. Bandera, Tanja Pejovic, Galina Lurie, Karoline Kuchenbaecker, Mariusz Bidziński, Chanel E. Smart, Maartje J. Hooning, Jose Ignacio Arias Perez, Anne-Marie Gerdes, L. Rogmann, Christoph Engel, Harvey A. Risch, Ignacio Blanco, Isabel dos Santos Silva, Hoda Anton-Culver, Camilla Krakstad, Volker Arndt, Foluso O. Ademuyiwa, Frans B. L. Hogervorst, Stacey L. Edwards, Florian Heitz, Veli-Matti Kosma, Beth Y. Karlan, Robert A. Vierkant, Irene L. Andrulis, Agnieszka Dansonka-Mieszkowska, Hanne Meijers-Heijboer, Alison M. Dunning, Sabapathy P. Balasubramanian, Penny Soucy, Edwin S. Iversen, Heli Nevanlinna, Celeste Leigh Pearce, Melissa C. Southey, Howard C. Shen, Kenneth Muir, Jolanta Lissowska, Clareann H. Bunker, Judy Garber, David Van Den Berg, Yin Ling Woo, Brigitte Bressac-de Paillerets, Rebecca Hein, Norbert Arnold, Saila Kauppila, Lisa Walker, Cezary Cybulski, Estrid Høgdall, Anthony J. Swerdlow, Robert Winqvist, Susanne K. Kjaer, Christa Stegmaier, Kazuo Tajima, Caroline Baynes, Valerie Gaborieau, Keitaro Matsuo, Ed Dicks, Irene Orlow, Torben A Kruse, Rachel Palmieri Weber, David E. Goldgar, Anna Jakubowska, Honglin Song, Antonis C. Antoniou, Paul D.P. Pharoah, Katja K.H. Aben, Lambertus A. Kiemeney, Laurence Faivre, Stefan Nickels, Joellen M. Schildkraut, Yu Tang Gao, Valerie McGuire, Charles L. Shapiro, Sebastian M. Armasu, Katherine L. Nathanson, Marjanka K. Schmidt, Susan L. Neuhausen, Jolanta Kupryjanczyk, Janet E. Olson, Nicolas Wentzensen, Dong Young Noh, Maya Ghoussaini, Ian G. Campbell, Annegien Broeks, Gustavo C. Rodriguez, Rebecca L. Johnston, Shan Wang-Gohrke, Monica Barile, Vesa Kataja, Melanie Maranian, Shahana Ahmed, Christof Sohn, Julie M. Cunningham, Weiva Sieh, Shani Shimon Paluch, Riccardo Dolcetti, John W.M. Martens, Manjeet K. Bolla, Shelley S. Tworoger, Robert S. Brown, Allan Jensen, Hui Miao, Boris Winterhoff, Mari K. Halle, Arndt Hartmann, Loris Bernard, Brian E. Henderson, Els Wauters, Carl Blomqvist, Daniel O. Stram, Karen A. Pooley, Roberta B. Ness, James Paul, Hilda A. Pickett, Wei Zheng, Sandra Deming-Halverson, Soo Hwang Teo, Andrew Lee, Thomas A. Sellers, Philip Iau, D. Gareth Evans, Françis Bacot, Sunil R. Lakhani, Qin Wang, Nick Orr, Celine M. Vachon, Edith Olah, Gong Yang, Svend Aage Engelholm, Martine Dumont, Linda S. Cook, Daniel C. Tessier, Evgeny N. Imyanitov, Paolo Radice, Mikael Hartman, Annika Lindblom, John R. McLaughlin, Radka Platte, Jenny Permuth-Wey, Keun-Young Yoo, Andrew Berchuck, Roger R. Reddel, M. John Kennedy, Toru Nakanishi, Allison F. Vitonis, Melissa C. Larson, Anna H. Wu, Helmut Deissler, Giuseppe Giannini, Barbara Wappenschmidt, Tomasz Byrski, M. Kamran Ikram, Natalia Antonenkova, Banu Arun, Peter Hillemanns, William Blot, Siti Zawiah Omar, Sue Healey, Trevor Cole, Cheng Har Yip, Matthias Dürst, Mark E. Robson, Roger L. Milne, Timothy R. Rebbeck, Jaana M. Hartikainen, Mieke Kriege, C. Ellen van der Schoot, Hansjoerg Plendl, Yasushi Yatabe, Jan C. Oosterwijk, Claus Høgdall, Rob A. E. M. Tollenaar, Jacek Gronwald, Yi Lu, Kate Lawrenson, Michael D. Stutz, Chia-Ni Hsiung, Alvaro N.A. Monteiro, Maren Weischer, Philipp Harter, Nicola Miller, Lisa B. Signorello, Katarzyna Durda, Peter Lichtner, Ritu Salani, Alfons Meindl, Montserrat Garcia-Closas, George Fountzilas, Uffe Birk Jensen, Thomas Brüning, Laura Baglietto, Anne M. van Altena, Kristine M. Hillman, Bernard Peissel, Trinidad Caldés, Rosemarie Davidson, Julian Barwell, Peter Devilee, Jenny Lester, Qiuyin Cai, Heiko Müller, Jyh Cherng Yu, Kerstin Rhiem, Muy Kheng Tea, Sharon A. Savage, Åke Borg, Daniel Vincent, Antoinette Hollestelle, Katarzyna Jaworska, Mat Adenan Noor Azmi, Yon Ko, Kimberly R. Kalli, Debra Frost, Martin Gore, Chiu-Chen Tseng, Georgia Chenevix-Trench, Pornthep Siriwanarangsan, Evelyn Despierre, Fergus J. Couch, Vijayalakshmi Shridhar, Artitaya Lophatananon, Amanda B. Spurdle, Joe Dennis, Ute Hamann, Vessela N. Kristensen, Frederik Marmé, Jonathan Tyrer, Arja Jukkola-Vuorinen, Wei Lu, Peter A. Fasching, Bruno Buecher, Kristiina Aittomäki, Kirsten B. Moysich, Lesley McGuffog, Mine S. Cicek, Guillermo Pita, Arjen R. Mensenkamp, Agnes Jager, Catherine M. Phelan, Jacques Simard, Ming-Feng Hou, Hiroji Iwata, James M. Flanagan, Elena Fineberg, Susan M. Domchek, Csilla Szabo, Diether Lambrechts, Anja Rudolph, Daehee Kang, Gottfried E. Konecny, Eitan Friedman, Argyrios Ziogas, Arto Mannermaa, Susan Peock, Matti A. Rookus, Christian F. Singer, Claire Mulot, Siranoush Manoukian, Johanna Rantala, Helen Tsimiklis, Gord Glendon, Pierre Laurent-Puig, Barbara Brouwers, Filomena Ficarazzi, Jonine D. Figueroa, Anne-Bine Skytte, Caroline Seynaeve, Christian Sutter, Rita K. Schmutzler, Julian Peto, Jeffrey N. Weitzel, Kathryn L. Terry, Børge G. Nordestgaard, Simon A. Gayther, Barbara Burwinkel, Ira Schwaab, Steven A. Narod, Elisabeth Wik, Ralf Bützow, Marco Montagna, Mark H. Greene, Linde M. Braaf, Janusz Menkiszak, Kamila Czene, Sarah Stewart-Brown, Kees E. P. van Roozendaal, Andreas Schneeweiss, Daniel Barrowdale, Elinor J. Sawyer, Alice S. Whittemore, Marc T. Goodman, Judith E. Brown, Kunle Odunsi, John L. Hopper, Nina Ditsch, Leon F.A.G. Massuger, Hermann Brenner, Joaquin J. Garcia, Xianshu Wang, Susan L. Slager, Aleksandra Tołoczko-Grabarek, Sylvie Mazoyer, Diana Eccles, Yik Ying Teo, Iwona K. Rzepecka, Bernardo Bonanni, Sara Margolin, Daniela Zaffaroni, Yew Ching Teh, Ans M Wvan Den Ouweland, Bent Ejlertsen, Maria Soller, Mitul Shah, Matthias W. Beckmann, Elizabeth M. Poole, J. Margriet Collée, Lorna Rodriguez-Rodriguez, Sandrina Lambrechts, Daniel W. Cramer, Douglas F. Easton, Virginie Caux-Moncoutier, Mads Thomassen, Keith Humphreys, ~, Landsteiner Laboratory, Clinical Haematology, CCA -Cancer Center Amsterdam, ARD - Amsterdam Reproduction and Development, Human Genetics, MUMC+: DA KG Lab Centraal Lab (9), Genetica & Celbiologie, RS: GROW - School for Oncology and Reproduction, Human genetics, CCA - Oncogenesis, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Clinical Genetics, Cardiothoracic Surgery, and Medical Oncology

Subjects
Telomerase, Messenger, Càncer d'ovari, Estrogen receptor, Aetiology, screening and detection [ONCOL 5], 0302 clinical medicine, Breast cancer, Risk Factors, Alternative Splicing, Biomarkers, Tumor, Breast Neoplasms, Case-Control Studies, Chromatin, DNA Methylation, Female, Gene Expression Profiling, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Luciferases, Oligonucleotide Array Sequence Analysis, Ovarian Neoplasms, Polymorphism, Single Nucleotide, RNA, Messenger, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Telomere, Genetics, BUCCAL CELLS, 0303 health sciences, Tumor, Telòmer, GENETIC-VARIATION, COMMON VARIANTS, Single Nucleotide, tert-clptm1l locus, genome-wide association, genetic-variation, susceptibility loci, buccal cells, fibroblasts, common variants, carcinoma, reverse-transcriptase htert, metaanalysis, Aetiology, screening and detection Immune Regulation [ONCOL 5], 3. Good health, Tumor Markers, Biological, 030220 oncology & carcinogenesis, FIBROBLASTS, SUSCEPTIBILITY LOCI, CARCINOMA, Single-nucleotide polymorphism, Biology, Article, Càncer de mama, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Translational research [ONCOL 3], Ovarian cancer, medicine, Polymorphism, Allele, GENOME-WIDE ASSOCIATION, METAANALYSIS, 030304 developmental biology, Molecular epidemiology Aetiology, screening and detection [NCEBP 1], Breast cancer susceptibility, Hereditary cancer and cancer-related syndromes [ONCOL 1], Translational research Genomic disorders and inherited multi-system disorders [ONCOL 3], medicine.disease, Molecular biology, TERT-CLPTM1L LOCUS, Minor allele frequency, RNA, Biomarkers, REVERSE-TRANSCRIPTASE HTERT
Abstract

Journal article TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ~480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 × 10!-7), lower risks for estrogen receptor (ER)-negative (P = 1.0 × 10!-8) and BRCA1 mutation carrier (P = 1.1 × 10!-5) breast cancers and altered promoter assay signal. The minor allele at the peak 2 SNP rs7705526 associates with longer telomeres (P = 2.3 × 10!-14), higher risk of low-malignant-potential ovarian cancer (P = 1.3 × 10!-15) and greater promoter activity. The minor alleles at the peak 3 SNPs rs10069690 and rs2242652 increase ER-negative (P = 1.2 × 10!-12) and BRCA1 mutation carrier (P = 1.6 × 10!-14) breast and invasive ovarian (P = 1.3 × 10!-11) cancer risks but not via altered telomere length. The cancer risk alleles of rs2242652 and rs10069690, respectively, increase silencing and generate a truncated TERT splice variant. European Commission Seventh Framework Programme (agreement 223175-HEALTH-F2-2009-223175); Cancer Research UK (C1287/A10118 and C1287/A12014) peer-reviewed

Published
2013
Full Text
View/download PDF

177. Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy

Author

Antonio Russo, Giovanna Masala, Paolo Radice, Stefania Tommasi, Domenico Palli, Piera Rizzolo, Veronica Graziano, Anna Sara Navazio, Laura Ottini, Alessandra Viel, Mario Falchetti, Cristina D'Amico, Giuseppe Giannini, Laura Cortesi, M. Barile, M. Montagna, Siranoush Manoukian, Simonetta Bianchi, Paolo Peterlongo, Ines Zanna, Valentina Silvestri, L. Varesco, Calogero Saieva, Ottini, L, Silvestri, V, Saieva, C, Rizzolo, P, Zanna, I, Falchetti, M, Masala, G, Navazio, AS, Graziano, V, Bianchi, S, Manoukian, S, Barile, M, Peterlongo, P, D'Amico, C, Veresco, L, Tommasi, S, Russo, A, Giannini, G, Cortesi, L, Viel, A, Montagna, M, Radice, P, and Palli, D

Subjects
Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Multivariate analysis, Settore MED/06 - Oncologia Medica, Clinicopathological characteristic, BRCA1/2, Clinicopathological characteristics, ER/PR status, Low-penetrance breast cancer alleles, Male breast cancer, SNPs, Single-nucleotide polymorphism, Polymorphism, Single Nucleotide, ER/PR statu, Breast Neoplasms, Male, Breast cancer, Internal medicine, Genotype, medicine, Humans, Genetic Predisposition to Disease, Allele, Receptor, Fibroblast Growth Factor, Type 2, Low-penetrance breast cancer allele, Alleles, Aged, Aged, 80 and over, business.industry, Estrogen Receptor alpha, High Mobility Group Proteins, clinicopathological characteristics, Middle Aged, medicine.disease, Penetrance, er/pr status, TOX3, Italy, Receptors, Estrogen, Case-Control Studies, Multivariate Analysis, Trans-Activators, low-penetrance breast cancer alleles, business, Apoptosis Regulatory Proteins, Receptors, Progesterone, male breast cancer, brca1/2, snps
Abstract

It is well-known that male breast cancer (MBC) susceptibility is mainly due to high-penetrance BRCA1/2 mutations. Here, we investigated whether common low-penetrance breast cancer (BC) susceptibility alleles may influence MBC risk in Italian population and whether variant alleles may be associated with specific clinicopathological features of MBCs. In the frame of the Italian Multicenter Study on MBC, we genotyped 413 MBCs and 745 age-matched male controls at 9 SNPs annotating known BC susceptibility loci. By multivariate logistic regression models, we found a significant increased MBC risk for 3 SNPs, in particular, with codominant models, for rs2046210/ESR1 (OR = 1.71; 95 % CI: 1.43–2.05; p = 0.0001), rs3803662/TOX3 (OR = 1.59; 95 % CI: 1.32–1.92; p = 0.0001), and rs2981582/FGFR2 (OR = 1.26; 95 % CI: 1.05–1.50; p = 0.013). Furthermore, we showed that the prevalence of the risk genotypes of ESR1 tended to be higher in ER− tumors (p = 0.062). In a case–case multivariate analysis, a statistically significant association between ESR1 and ER− tumors was found (OR = 1.88; 95 % CI: 1.03–3.49; p = 0.039). Overall, our data, based on a large and well-characterized MBC series, support the hypothesis that common low-penetrance BC susceptibility alleles play a role in MBC susceptibility and, interestingly, indicate that ESR1 is associated with a distinct tumor subtype defined by ER-negative status.

Published
2013

178. X chromosome inactivation pattern in BRCA gene mutation carriers

Author

Monica Miozzo, Silvia Tabano, Siranoush Manoukian, Mariarosaria Calvello, Bernard Peissel, F.R. Grati, Valeria Pensotti, Claudia Allemani, Silva M. Sirchia, John Burn, Patrizia Colapietro, Paolo Radice, Sara Pizzamiglio, Paolo Verderio, Manoukian, S, Verderio, P, Tabano, S, Colapietro, P, Pizzamiglio, S, Grati, F, Calvello, M, Peissel, B, Burn, J, Pensotti, V, Allemani, C, Sirchia, S, Radice, P, and Miozzo, M

Subjects
Oncology, Adult, medicine.medical_specialty, Heterozygote, Cancer Research, DNA Mutational Analysis, BRCA gene, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, Predictive Value of Test, Gene mutation, Biology, X-inactivation, DNA Mutational Analysi, Young Adult, Predictive Value of Tests, X Chromosome Inactivation, Internal medicine, medicine, Humans, Chemotherapy, Aged, Genetics, Ovarian Neoplasms, Aged, 80 and over, Ovarian Neoplasm, BRCA mutation, Carcinoma, Case-control study, Cancer, HUMARA test, Odds ratio, Middle Aged, medicine.disease, Ageing, Receptors, Androgen, Case-Control Studies, Mutation (genetic algorithm), Mutation, Female, Ovarian cancer, Case-Control Studie, Breast Neoplasm, Human
Abstract

An association of preferential X chromosome inactivation (XCI) with BRCA gene status and breast/ovarian cancer risk has been reported. We evaluated XCI in a large group of BRCA mutation carriers compared to non-carriers and investigated associations between preferential XCI (≥90:10) and age, mutated gene, cancer development and chemotherapy. XCI was analysed by human androgen receptor (HUMARA) assay and pyrosequencing in 437 BRCA1 or BRCA2 mutation carriers and 445 age-matched controls. The distribution of XCI patterns in the two groups was compared by logistic regression analysis. The association between preferential XCI and selected variables was investigated in both univariate and multivariate fashion. In univariate analyses preferential XCI was not significantly associated with the probability of being a BRCA mutation carrier, nor with cancer status, whereas chemotherapeutic regime and age both showed a significant association. In multivariate analysis only age maintained significance (odds ratio, 1.056; 95% confidence interval, 1.016-1.096). Our findings do not support the usefulness of XCI analysis for the identification of BRCA mutation carriers and cancer risk assessment. The increasing preferential XCI frequency with ageing and the association with chemotherapy justify extending the investigation to other categories of female cancer patients to identify possible X-linked loci implicated in cell survival. © 2012 Elsevier Ltd. All rights reserved.

Published
2013

179. Abstract 1859: Bioinformatic and experimental evaluation of regulatory variants in breast cancer susceptibility genes

Author

Amanda B. Spurdle, Paolo Peterlongo, Ana Vega, Thomas van Overeem Hansen, Siranoush Manoukian, Maria A. Caligo, Melissa A. Brown, Philip J. Whiley, Brooke L. Brewster, Paolo Radice, Leslie Burke, Emma Tudini, Jan Sevcik, Marta Santamariña Pena, Etienne Rouleau, and Gaetana Gambino

Subjects
Genetics, Untranslated region, Cancer Research, Cancer, Biology, medicine.disease, Genome, Germline, Breast cancer, Oncology, Regulatory sequence, medicine, Allele, Gene
Abstract

Many germline DNA sequence variants in gene regulatory elements are associated with an increased risk of cancer. These include large genomic deletions of the promoter of the BRCA1 gene, through to single nucleotide variants in the promoter, UTRs and long-range enhancers of multiple other cancer related genes. Next generation sequence analysis of early onset and familial breast cancer cases is currently identifying an escalating number of variants in non-coding regions of the genome, however for most of these the significance in unknown. This project aims to determine the functional and clinical significance of breast cancer associated variants in regulatory regions of BRCA1 and BRCA2, as part of an international collaborative project arising from the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium. To date over two hundred variants mapping to promoter, UTR and deep intronic regions have been identified in early onset or familial breast cancer patients that have no identifiable coding or splicing changes in BRCA1 or BRCA2. Through a pipeline of bioinformatics analyses using ENCODE datasets, these variants have been prioritized for experimental evaluation. This has lead to the identification of several variants that significantly alter the regulation of BRCA1 or BRCA2 expression, through mechanisms including altered binding of transcription factors and microRNAs. These studies will lay the groundwork for comprehensive statistical analyses, in which bioinformatics and experimental data is combined with clinical and genetic data to establish multifactorial risk prediction models that can ultimately be used in a clinical setting. Citation Format: Jan Sevcik, Leslie Burke, Gaetana Gambino, Brooke L. Brewster, Emma Tudini, Philip J. Whiley, Siranoush Manoukian, ENIGMA Consortium, Thomas van Overeem Hansen, Marta Santamariña Pena, Ana Vega, Maria A. Caligo, Paolo Radice, Paolo Peterlongo, Etienne Rouleau, Amanda B. Spurdle, Melissa A. Brown. Bioinformatic and experimental evaluation of regulatory variants in breast cancer susceptibility genes. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1859.

Published
2016
Full Text
View/download PDF

180. Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors

Author

Fergus J, Couch, Xianshu, Wang, Lesley, McGuffog, Andrew, Lee, Curtis, Olswold, Karoline B, Kuchenbaecker, Penny, Soucy, Zachary, Fredericksen, Daniel, Barrowdale, Joe, Dennis, Mia M, Gaudet, Ed, Dicks, Matthew, Kosel, Sue, Healey, Olga M, Sinilnikova, Adam, Lee, François, Bacot, Daniel, Vincent, Frans B L, Hogervorst, Susan, Peock, Dominique, Stoppa-Lyonnet, Anna, Jakubowska, Paolo, Radice, Rita Katharina, Schmutzler, Susan M, Domchek, Marion, Piedmonte, Christian F, Singer, Eitan, Friedman, Mads, Thomassen, Thomas V O, Hansen, Susan L, Neuhausen, Csilla I, Szabo, Ignacio, Blanco, Mark H, Greene, Beth Y, Karlan, Judy, Garber, Catherine M, Phelan, Jeffrey N, Weitzel, Marco, Montagna, Edith, Olah, Irene L, Andrulis, Andrew K, Godwin, Drakoulis, Yannoukakos, David E, Goldgar, Trinidad, Caldes, Heli, Nevanlinna, Ana, Osorio, Mary Beth, Terry, Mary B, Daly, Elizabeth J, van Rensburg, Ute, Hamann, Susan J, Ramus, Amanda Ewart, Toland, Maria A, Caligo, Olufunmilayo I, Olopade, Nadine, Tung, Kathleen, Claes, Mary S, Beattie, Melissa C, Southey, Evgeny N, Imyanitov, Marc, Tischkowitz, Ramunas, Janavicius, Esther M, John, Ava, Kwong, Orland, Diez, Judith, Balmaña, Rosa B, Barkardottir, Banu K, Arun, Gad, Rennert, Soo-Hwang, Teo, Patricia A, Ganz, Ian, Campbell, Annemarie H, van der Hout, Carolien H M, van Deurzen, Caroline, Seynaeve, Encarna B, Gómez Garcia, Flora E, van Leeuwen, Hanne E J, Meijers-Heijboer, Johannes J P, Gille, Margreet G E M, Ausems, Marinus J, Blok, Marjolijn J L, Ligtenberg, Matti A, Rookus, Peter, Devilee, Senno, Verhoef, Theo A M, van Os, Juul T, Wijnen, Debra, Frost, Steve, Ellis, Elena, Fineberg, Radka, Platte, D Gareth, Evans, Louise, Izatt, Rosalind A, Eeles, Julian, Adlard, Diana M, Eccles, Jackie, Cook, Carole, Brewer, Fiona, Douglas, Shirley, Hodgson, Patrick J, Morrison, Lucy E, Side, Alan, Donaldson, Catherine, Houghton, Mark T, Rogers, Huw, Dorkins, Jacqueline, Eason, Helen, Gregory, Emma, McCann, Alex, Murray, Alain, Calender, Agnès, Hardouin, Pascaline, Berthet, Capucine, Delnatte, Catherine, Nogues, Christine, Lasset, Claude, Houdayer, Dominique, Leroux, Etienne, Rouleau, Fabienne, Prieur, Francesca, Damiola, Hagay, Sobol, Isabelle, Coupier, Laurence, Venat-Bouvet, Laurent, Castera, Marion, Gauthier-Villars, Mélanie, Léoné, Pascal, Pujol, Sylvie, Mazoyer, Yves-Jean, Bignon, Elżbieta, Złowocka-Perłowska, Jacek, Gronwald, Jan, Lubinski, Katarzyna, Durda, Katarzyna, Jaworska, Tomasz, Huzarski, Amanda B, Spurdle, Alessandra, Viel, Bernard, Peissel, Bernardo, Bonanni, Giulia, Melloni, Laura, Ottini, Laura, Papi, Liliana, Varesco, Maria Grazia, Tibiletti, Paolo, Peterlongo, Sara, Volorio, Siranoush, Manoukian, Valeria, Pensotti, Norbert, Arnold, Christoph, Engel, Helmut, Deissler, Dorothea, Gadzicki, Andrea, Gehrig, Karin, Kast, Kerstin, Rhiem, Alfons, Meindl, Dieter, Niederacher, Nina, Ditsch, Hansjoerg, Plendl, Sabine, Preisler-Adams, Stefanie, Engert, Christian, Sutter, Raymonda, Varon-Mateeva, Barbara, Wappenschmidt, Bernhard H F, Weber, Brita, Arver, Marie, Stenmark-Askmalm, Niklas, Loman, Richard, Rosenquist, Zakaria, Einbeigi, Katherine L, Nathanson, Timothy R, Rebbeck, Stephanie V, Blank, David E, Cohn, Gustavo C, Rodriguez, Laurie, Small, Michael, Friedlander, Victoria L, Bae-Jump, Anneliese, Fink-Retter, Christine, Rappaport, Daphne, Gschwantler-Kaulich, Georg, Pfeiler, Muy-Kheng, Tea, Noralane M, Lindor, Bella, Kaufman, Shani, Shimon Paluch, Yael, Laitman, Anne-Bine, Skytte, Anne-Marie, Gerdes, Inge Sokilde, Pedersen, Sanne Traasdahl, Moeller, Torben A, Kruse, Uffe Birk, Jensen, Joseph, Vijai, Kara, Sarrel, Mark, Robson, Noah, Kauff, Anna Marie, Mulligan, Gord, Glendon, Hilmi, Ozcelik, Bent, Ejlertsen, Finn C, Nielsen, Lars, Jønson, Mette K, Andersen, Yuan Chun, Ding, Linda, Steele, Lenka, Foretova, Alex, Teulé, Conxi, Lazaro, Joan, Brunet, Miquel Angel, Pujana, Phuong L, Mai, Jennifer T, Loud, Christine, Walsh, Jenny, Lester, Sandra, Orsulic, Steven A, Narod, Josef, Herzog, Sharon R, Sand, Silvia, Tognazzo, Simona, Agata, Tibor, Vaszko, Joellen, Weaver, Alexandra V, Stavropoulou, Saundra S, Buys, Atocha, Romero, Miguel, de la Hoya, Kristiina, Aittomäki, Taru A, Muranen, Mercedes, Duran, Wendy K, Chung, Adriana, Lasa, Cecilia M, Dorfling, Alexander, Miron, Javier, Benitez, Leigha, Senter, Dezheng, Huo, Salina B, Chan, Anna P, Sokolenko, Jocelyne, Chiquette, Laima, Tihomirova, Tara M, Friebel, Bjarni A, Agnarsson, Karen H, Lu, Flavio, Lejbkowicz, Paul A, James, Per, Hall, Alison M, Dunning, Daniel, Tessier, Julie, Cunningham, Susan L, Slager, Chen, Wang, Steven, Hart, Kristen, Stevens, Jacques, Simard, Tomi, Pastinen, Vernon S, Pankratz, Kenneth, Offit, Douglas F, Easton, Georgia, Chenevix-Trench, and Antonis C, Antoniou

Subjects
BRCA2 Protein, Ovarian Neoplasms, Heterozygote, endocrine system diseases, Genotype, BRCA1 Protein, Breast Neoplasms, Middle Aged, Prognosis, Polymorphism, Single Nucleotide, Risk Factors, Mutation, Humans, Medicine, Female, Genetic Predisposition to Disease, skin and connective tissue diseases, Biology, Genome-Wide Association Study, Research Article
Abstract

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10−8, HR = 1.14, 95% CI: 1.09–1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10−8, HR = 1.27, 95% CI: 1.17–1.38) and 4q32.3 (rs4691139, P = 3.4×10−8, HR = 1.20, 95% CI: 1.17–1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2×10−4). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers., Author Summary BRCA1 mutation carriers have increased and variable risks of breast and ovarian cancer. To identify modifiers of breast and ovarian cancer risk in this population, a multi-stage GWAS of 14,351 BRCA1 mutation carriers was performed. Loci 1q32 and TCF7L2 at 10q25.3 were associated with breast cancer risk, and two loci at 4q32.2 and 17q21.31 were associated with ovarian cancer risk. The 4q32.3 ovarian cancer locus was not associated with ovarian cancer risk in the general population or in BRCA2 carriers and is the first indication of a BRCA1-specific risk locus for either breast or ovarian cancer. Furthermore, modeling the influence of these modifiers on cumulative risk of breast and ovarian cancer in BRCA1 mutation carriers for the first time showed that a wide range of individual absolute risks of each cancer can be estimated. These differences suggest that genetic risk modifiers may be incorporated into the clinical management of BRCA1 mutation carriers.

Published
2012

181. Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors

Author

Mia M, Gaudet, Karoline B, Kuchenbaecker, Joseph, Vijai, Robert J, Klein, Tomas, Kirchhoff, Lesley, McGuffog, Daniel, Barrowdale, Alison M, Dunning, Andrew, Lee, Joe, Dennis, Sue, Healey, Ed, Dicks, Penny, Soucy, Olga M, Sinilnikova, Vernon S, Pankratz, Xianshu, Wang, Ronald C, Eldridge, Daniel C, Tessier, Daniel, Vincent, Francois, Bacot, Frans B L, Hogervorst, Susan, Peock, Dominique, Stoppa-Lyonnet, Paolo, Peterlongo, Rita K, Schmutzler, Katherine L, Nathanson, Marion, Piedmonte, Christian F, Singer, Mads, Thomassen, Thomas v O, Hansen, Susan L, Neuhausen, Ignacio, Blanco, Mark H, Greene, Judith, Garber, Jeffrey N, Weitzel, Irene L, Andrulis, David E, Goldgar, Emma, D'Andrea, Trinidad, Caldes, Heli, Nevanlinna, Ana, Osorio, Elizabeth J, van Rensburg, Adalgeir, Arason, Gad, Rennert, Ans M W, van den Ouweland, Annemarie H, van der Hout, Carolien M, Kets, Cora M, Aalfs, Juul T, Wijnen, Margreet G E M, Ausems, Debra, Frost, Steve, Ellis, Elena, Fineberg, Radka, Platte, D Gareth, Evans, Chris, Jacobs, Julian, Adlard, Marc, Tischkowitz, Mary E, Porteous, Francesca, Damiola, Lisa, Golmard, Laure, Barjhoux, Michel, Longy, Muriel, Belotti, Sandra Fert, Ferrer, Sylvie, Mazoyer, Amanda B, Spurdle, Siranoush, Manoukian, Monica, Barile, Maurizio, Genuardi, Norbert, Arnold, Alfons, Meindl, Christian, Sutter, Barbara, Wappenschmidt, Susan M, Domchek, Georg, Pfeiler, Eitan, Friedman, Uffe Birk, Jensen, Mark, Robson, Sohela, Shah, Conxi, Lazaro, Phuong L, Mai, Javier, Benitez, Melissa C, Southey, Marjanka K, Schmidt, Peter A, Fasching, Julian, Peto, Manjeet K, Humphreys, Qin, Wang, Kyriaki, Michailidou, Elinor J, Sawyer, Barbara, Burwinkel, Pascal, Guénel, Stig E, Bojesen, Roger L, Milne, Hermann, Brenner, Magdalena, Lochmann, Kristiina, Aittomäki, Thilo, Dörk, Sara, Margolin, Arto, Mannermaa, Diether, Lambrechts, Jenny, Chang-Claude, Paolo, Radice, Graham G, Giles, Christopher A, Haiman, Robert, Winqvist, Peter, Devillee, Montserrat, García-Closas, Nils, Schoof, Maartje J, Hooning, Angela, Cox, Paul D P, Pharoah, Anna, Jakubowska, Nick, Orr, Anna, González-Neira, Guillermo, Pita, M Rosario, Alonso, Per, Hall, Fergus J, Couch, Jacques, Simard, David, Altshuler, Douglas F, Easton, Georgia, Chenevix-Trench, Antonis C, Antoniou, and Kenneth, Offit

Subjects
Adult, BRCA2 Protein, Heterozygote, Genotype, BRCA1 Protein, Breast Neoplasms, Middle Aged, Polymorphism, Single Nucleotide, Risk Factors, Mutation, Genetics, Cancer Genetics, Genome-Wide Association Studies, Humans, Chromosomes, Human, Pair 6, Female, Genetic Predisposition to Disease, skin and connective tissue diseases, Biology, Alleles, Aged, Genome-Wide Association Study, Research Article
Abstract

Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80–0.90, P = 3.9×10−8). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer., Author Summary Women who carry BRCA2 mutations have an increased risk of breast cancer that varies widely. To identify common genetic variants that modify the breast cancer risk associated with BRCA2 mutations, we have built upon our previous work in which we examined genetic variants across the genome in relation to breast cancer risk among BRCA2 mutation carriers. Using a custom genotyping platform with 211,155 genetic variants known as single nucleotide polymorphisms (SNPs), we genotyped 3,881 women who had breast cancer and 4,330 women without breast cancer, which represents the largest possible, international collection of BRCA2 mutation carriers. We identified that a SNP located at 6p24 in the genome was associated with lower risk of breast cancer. Importantly, this SNP was not associated with breast cancer in BRCA1 mutation carriers or in a general population of women, indicating that the breast cancer association with this SNP might be specific to BRCA2 mutation carriers. Combining this BRCA2-specific SNP with 13 other breast cancer risk SNPs also known to modify risk in BRCA2 mutation carriers, we were able to derive a risk prediction model that could be useful in helping women with BRCA2 mutations weigh their risk-reduction strategy options.

Published
2012

182. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

Author

Ramus, Susan J., Antoniou, Antonis C., Kuchenbaecker, Karoline B., Penny, Soucy, Jonathan, Beesley, Xiaoqing, Chen, Lesley, Mcguffog, Sinilnikova, Olga M., Sue, Healey, Daniel, Barrowdale, Andrew, Lee, Mads, Thomassen, Anne Marie Gerdes, Kruse, Torben A., Uffe Birk Jensen, Anne Bine Skytte, Caligo, Maria A., Annelie, Liljegren, Annika, Lindblom, Hakan, Olsson, Ulf, Kristoffersson, Marie Stenmark Askmalm, Swe Brca Melin, B., Swe, Brca, Domchek, Susan M., Domchek, Sm, Nathanson, Katherine L., Rebbeck, Timothy R., Anna, Jakubowska, Jan, Lubinski, Katarzyna, Jaworska, Katarzyna, Durda, Elzbieta, Złowocka, Jacek, Gronwald, Tomasz, Huzarski, Tomasz, Byrski, Cezary, Cybulski, Aleksandra Toloczko Grabarek, Ana, Osorio, Javier, Benitez, Mercedes, Duran, Maria Isabel Tejada, Ute, Hamann, Matti, Rookus, Van Leeuwen, Flora E., Aalfs, Cora M., Meijers Heijboer, Hanne E. J., Van Asperen, Christi J., Van Roozendaal, K. E. P., Nicoline, Hoogerbrugge, Collee, Margriet J., Margriet Collee, J., Mieke, Kriege, Hebon Van Der Luijt, R. B., Embrace, Embrace, Hebon, Susan, Peock, Debra, Frost, Ellis, Steve D., Radka, Platte, Elena, Fineberg, Gareth Evans, D., Fiona, Lalloo, Chris, Jacobs, Ros, Eeles, Julian, Adlard, Rosemarie, Davidson, Diana, Eccles, Trevor, Cole, Jackie, Cook, Joan, Paterson, Fiona, Douglas, Carole, Brewer, Shirley, Hodgson, Morrison, Patrick J., Lisa, Walker, Porteous, Mary E., John Kennedy, M., Harsh, Pathak, Godwin, Andrew K., Dominique Stoppa Lyonnet, Virginie Caux Moncoutier, Antoine Pauw, D. E., De Pauw, A., Marion Gauthier Villars, Sylvie, Mazoyer, Melanie, Leone, Alain, Calender, Christine, Lasset, Valerie, Bonadona, Agnes, Hardouin, Pascaline, Berthet, Yves Jean Bignon, Nancy, Uhrhammer, Laurence, Faivre, Catherine, Loustalot, Gemo, Saundra, Buys, Mary, Daly, Buys, Daly, S., Alex, Miron, Beth, Terry M., Mary Beth Terry, Terry, M. B., Chung, Wendy K., Esther, John M., John, Em, Melissa, Southey, David, Goldgar, Singer, Christian F., Muy Kheng Tea, Georg, Pfeiler, Anneliese Fink Retter, Hansen, Thomas V. O., Hansen, Tv, Bent, Ejlertsen, Oskar Th Johannsson, Kenneth, Offit, Tomas, Kirchhoff, Gaudet, Mia M., Joseph, Vijai, Mark, Robson, Marion, Piedmonte, Kelly Anne Phillips, Linda Van Le, Hoffman, James S., Amanda Ewart Toland, Ewart Toland, A., Marco, Montagna, Silvia, Tognazzo, Evgeny, Imyanitov, Claudine, Isaacs, Issacs, C., Ramunas, Janavicius, Conxi, Lazaro, Ignacio, Blanco, Eva, Tornero, Matilde, Navarro, Moysich, Kirsten B., Karlan, Beth Y., Jenny, Gross, Edith, Olah, Tibor, Vaszko, Soo Hwang Teo, Ganz, Patricia A., Beattie, Mary S., Dorfling, Cecelia M., Van Rensburg, Elizabeth J., Orland, Diez, Ava, Kwong, Schmutzler, Rita K., Barbara, Wappenschmidt, Christoph, Engel, Alfons, Meindl, Nina, Ditsch, Norbert, Arnold, Simone, Heidemann, Dieter, Niederacher, Sabine Preisler Adams, Dorotehea, Gadzicki, Raymonda Varon Mateeva, Helmut, Deissler, Andrea, Gehrig, Christian, Sutter, Karin, Kast, Britta, Fiebig, Dieter, Schafer, Trinidad, Caldes, Miguel De La Hoya, Heli, Nevanlinna, Kristiina, Aittomaki, Marie, Plante, Kconfab Spurdle, A. B., Kconfab, Neuhausen, Susan L., Neuhausen, Sl, Yuan Chun Ding, Xianshu, Wang, Noralane, Lindor, Zachary, Fredericksen, Shane Pankratz, V., Paolo, Peterlongo, Siranoush, Manoukian, Bernard, Peissel, Daniela, Zaffaroni, Bernardo, Bonanni, Loris, Bernard, Riccardo, Dolcetti, Laura, Papi, Ottini, Laura, Paolo, Radice, Greene, Mark H., Mai, Phuong L., Andrulis, Irene L., Gord, Glendon, Ocgn Ozcelik, H., Ocgn, Pharoah, Paul D. P., Pharoah, Pd, Gayther, Simon A., Jacques, Simard, Easton, Douglas F., Couch, Fergus J., Georgia Chenevix Trench, Behalf Of The Consortium Of Investigators Of Modifiers Of Brca1/2, O. N., Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Human Genetics, CCA -Cancer Center Amsterdam, ARD - Amsterdam Reproduction and Development, Universitat de Barcelona, Genetica & Celbiologie, MUMC+: DA KG Lab Centraal Lab (9), RS: CARIM School for Cardiovascular Diseases, RS: GROW - School for Oncology and Reproduction, and Clinical Genetics

Subjects
Oncology, endocrine system diseases, [SDV]Life Sciences [q-bio], Càncer d'ovari, DCN PAC - Perception action and control, Cohort Studies, Breast cancer, 0302 clinical medicine, brca1, brca2, Odds Ratio, Genetics (clinical), ComputingMilieux_MISCELLANEOUS, Ovarian Neoplasms, Genetics, 0303 health sciences, education.field_of_study, BRCA1 Protein, Hazard ratio, Middle Aged, 3. Good health, ovarian cancer, 030220 oncology & carcinogenesis, Female, Adult, Heterozygote, medicine.medical_specialty, Hereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1], Population, Single-nucleotide polymorphism, Biology, Ovarian Neoplasms - genetics, Polymorphism, Single Nucleotide, Article, Càncer de mama, 03 medical and health sciences, Germline mutation, SDG 3 - Good Health and Well-being, Translational research [ONCOL 3], Ovarian cancer, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, ddc:610, Genetics and epigenetic pathways of disease Translational research [NCMLS 6], education, Retrospective Studies, 030304 developmental biology, BRCA2 Protein, Hereditary cancer and cancer-related syndromes [ONCOL 1], association, Retrospective cohort study, snp, Odds ratio, BRCA1 Protein - genetics, medicine.disease, BRCA2 Protein - genetics, Mutation
Abstract

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 x 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 x 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 x 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer., link_to_OA_fulltext

Published
2012
Full Text
View/download PDF

183. The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians

Author

Monica Barile, Paolo Peterlongo, Laura Galastri, Loris Bernard, Sara Pizzamiglio, Domenico Sardella, Fernando Ravagnani, Siranoush Manoukian, Paolo Radice, Daniela Zaffaroni, Valentina Dall'Olio, Irene Catucci, Paolo Verderio, and Bernard Peissel

Subjects
Oncology, Risk, Cancer Research, medicine.medical_specialty, business.industry, Breast Neoplasms, medicine.disease, Polymorphism, Single Nucleotide, White People, MicroRNAs, Breast cancer, Italy, Internal medicine, Medicine, SNP, Humans, Female, Genetic Predisposition to Disease, Familial breast cancer, business
Published
2012

184. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy

Author

Stefania Tommasi, Paolo Radice, Laura Ottini, Mario Falchetti, Domenico Palli, Simonetta Bianchi, Valentina Silvestri, Giovanna Masala, Piera Rizzolo, Antonio Russo, Paolo Peterlongo, Marco Montagna, Alessandra Viel, Giuseppe Giannini, Siranoush Manoukian, Calogero Saieva, Ines Zanna, Liliana Varesco, Laura Cortesi, Monica Barile, Ottini, L, Silvestri, V, Rizzolo, P, Falchetti, M, Zanna, I, Saieva, C, Masala, G, Bianchi, S, Manoukian, S, Barile, M, Peterlongo, P, Varesco, L, Tommasi, S, Russo, A, Giannini, G, Cortesi, L, Viel, A, Montagna, M, Radice, P, and Palli, D

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Molecular subtypes, Settore MED/06 - Oncologia Medica, DNA Mutational Analysis, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, Male, Young Adult, clinical-pathologic features, brca2, brca1, male breast cancer, molecular subtypes, Breast cancer, Internal medicine, medicine, Carcinoma, Humans, Young adult, Family history, skin and connective tissue diseases, BRCA1, BRCA2, Clinical-pathologic features, Male breast cancer, Aged, Aged, 80 and over, Gynecology, business.industry, Carcinoma, Ductal, Breast, Middle Aged, medicine.disease, Italy, Immunohistochemistry, Ovarian cancer, business, Clinical-pathologic feature, Rare disease
Abstract

Recently, the number of studies on male breast cancer (MBC) has been increasing. However, as MBC is a rare disease there are difficulties to undertake studies to identify specific MBC subgroups. At present, it is still largely unknown whether BRCA-related breast cancer (BC) in men may display specific characteristics as it is for BRCA-related BC in women. To investigate the clinical–pathologic features of MBC in association with BRCA mutations we established a collaborative Italian Multicenter Study on MBC with the aim to recruit a large series of MBCs. A total of 382 MBCs, including 50 BRCA carriers, were collected from ten Italian Investigation Centres covering the whole country. In MBC patients, BRCA2 mutations were associated with family history of breast/ovarian cancer (p

Published
2012

185. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

Author

Antoniou, Antonis C., Kuchenbaecker, Karoline B., Penny, Soucy, Jonathan, Beesley, Xiaoqing, Chen, Lesley, Mcguffog, Andrew, Lee, Daniel, Barrowdale, Sue, Healey, Sinilnikova, Olga M., Caligo, Maria A., Niklas, Loman, Katja, Harbst, Annika, Lindblom, Brita, Arver, Richard, Rosenquist, Per, Karlsson, Kate, Nathanson, Susan, Domchek, Tim, Rebbeck, Anna, Jakubowska, Jan, Lubinski, Katarzyna, Jaworska, Katarzyna, Durda, Zlowocka Perlowska, E., Elzbieta Złowowcka Perłowska, Ana, Osorio, Mercedes, Duran, Raquel, Andres, Javier, Benitez, Ute, Hamann, Hogervorst, Frans B., Van, A., Van Os, Theo A., Senno, Verhoef, Meijers Heijboer, Hanne E. J., Juul, Wijnen, Gomez Garcia, Encarna B., Ligtenberg, Marjolijn J., Mieke, Kriege, Margriet Collee, J., Margreet Gem Ausems, Oosterwijk, Jan C., Susan, Peock, Debra, Frost, Ellis, Steve D., Radka, Platte, Elena, Fineberg, Gareth Evans, D., Fiona, Lalloo, Chris, Jacobs, Ros, Eeles, Julian, Adlard, Rosemarie, Davidson, Trevor, Cole, Jackie, Cook, Joan, Paterson, Fiona, Douglas, Carole, Brewer, Shirley, Hodgson, Morrison, Patrick J., Lisa, Walker, Rogers, Mark T., Alan, Donaldson, Huw, Dorkins, Godwin, Andrew K., Betsy, Bove, Dominique Stoppa Lyonnet, Claude, Houdayer, Bruno, Buecher, De Pauw, A., Antoine Pauw, D. E., Sylvie, Mazoyer, Alain, Calender, Melanie, Leone, Brigitte Bressac De Paillerets, Olivier, Caron, Hagay, Sobol, Marc, Frenay, Fabienne, Prieur, Sandra, Ferrer, Isabelle, Mortemousque, Saundra, Buys, Mary, Daly, Alexander, Miron, Terry, Mb, Terry, Mu, Mary, Terry, Hopper, John L., John, Em, Esther, John M., Melissa, Southey, David, Goldgar, Singer, Christian F., Anneliese Fink Retter, Muy Kheng Tea, Geschwantler Kaulich, D., Daphne, Kaulich, Hansen, Thomas V. O., Nielsen, Finn C., Barkardottir, Rosa B., Mia, Gaudet, Tomas, Kirchhoff, Joseph, V., Joseph, Vijai, Ana Dutra Clarke, Kenneth, Offit, Marion, Piedmonte, Judy, Kirk, David, Cohn, Jean, Hurteau, John, Byron, James, Fiorica, Toland, Amanda E., Marco, Montagna, Cristina, Oliani, Evgeny, Imyanitov, Claudine, Isaacs, Laima, Tihomirova, Ignacio, Blanco, Conxi, Lazaro, Alex, Teule, Del Valle, J., Gayther, Simon A., Kunle, Odunsi, Jenny, Gross, Karlan, Beth Y., Edith, Olah, Soo Hwang Teo, Ganz, Patricia A., Beattie, Mary S., Dorfling, Cecelia M., Jansen Van Rensburg, E., Elizabeth Van Rensburg, Orland, Diez, Ava, Kwong, Schmutzler, Rita K., Barbara, Wappenschmidt, Christoph, Engel, Alfons, Meindl, Nina, Ditsch, Norbert, Arnold, Simone, Heidemann, Dieter, Niederacher, Sabine Preisler Adams, Dorothea, Gadzicki, Raymonda Varon Mateeva, Helmut, Deissler, Andrea, Gehrig, Christian, Sutter, Karin, Kast, Britta, Fiebig, Dieter, Schafer, Trinidad, Caldes, Miguel De La Hoya, Heli, Nevanlinna, Muranen, Taru A., Bernard, Lesperance, Spurdle, Amanda B., Neuhausen, Susan L., Ding, Yuan C., Xianshu, Wang, Zachary, Fredericksen, Pankratz, Vernon S., Lindor, Noralane M., Paolo, Peterlongo, Siranoush, Manoukian, Bernard, Peissel, Daniela, Zaffaroni, Bernardo, Bonanni, Loris, Bernard, Riccardo, Dolcetti, Laura, Papi, Ottini, Laura, Paolo, Radice, Greene, Mark H., Loud, Jennifer T., Andrulis, Irene L., Hilmi, Ozcelik, Anna, Mulligan, Gord, Glendon, Mads, Thomassen, Anne Marie Gerdes, Jensen, Uffe B., Anne Bine Skytte, Kruse, Torben A., Georgia Chenevix Trench, Couch, Fergus J., Jacques, Simard, Easton, Douglas F., Swedish Breast, Cancer Study S. B., Facility, Research H., Study, E., Collaborators, Study G., Investigators, K., Swe Brca Cimba, Embrace, Hebon, Study Gemo Collaborators, Kconfab, Investigators, BMC, Ed., Collaborative Oncological Gene-environment Study - COGS - - EC:FP7:HEALTH2009-05-01 - 2014-01-31 - 223175 - VALID, Centre for Cancer Genetic Epidemiology, University of Cambridge [UK] (CAM), Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec, Genetics and Population Health Division, Queensland Institute of Medical Research, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Léon Bérard [Lyon]-Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Section of Genetic Oncology, University of Pisa - Università di Pisa, Department of Oncology, Lund University Hospital, Department of Clinical Genetics, Karolinska University Hospital [Stockholm], Department of Genetics and Pathology, Uppsala University-Rudbeck Laboratory, Sahlgrenska University Hospital [Gothenburg], Abramson Cancer Center, University of Pennsylvania-Perelman School of Medicine, University of Pennsylvania, International Hereditary Cancer Centre-Pomeranian Medical University [Szczecin] (PUM), Postgraduate School of Molecular Medicine, Warsaw Medical University, Human Genetics Group, Spanish National Cancer Research Centre, Biomedical Research Centre Network for Rare Diseases, CIBER de Enfermedades Raras (CIBERER), Institute of Biology and Molecular Genetics, Universidad de Valladolid [Valladolid] (UVa), Medical Oncology Division, Hospital Clínico de Zaragoza, Molecular Genetics of Breast Cancer, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Family Cancer Clinic, Netherlands Cancer Institute, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), VU Medical Center, Department of Clinical Genetics and GROM, School for Oncology and Developmental Biology, Department of Human Genetics, Radboud University [Nijmegen], Erasmus University Medical Center [Rotterdam] (Erasmus MC)-Family Cancer Clinic, Department of Clinical Molecular Genetics, University Medical Center [Utrecht], Department of Genetics, VU University Medical Center [Amsterdam], Genetic Medicine, Manchester Academic Health Sciences Centre-Central Manchester University Hospitals, Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, Oncogenetics Team, The Institute of Cancer Research-Royal Marsden NHS Foundation Trust, Yorkshire Regional Genetics Service, Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, West Midlands Regional Genetics Service, Birmingham Women's and Children's NHS Foundation Trust, Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Addenbrookes Hospital, Institute of Human Genetics, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Royal Devon & Exeter Hospital, Medical Genetics Unit, University College of London [London] (UCL), Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, Department of Medical Genetics, Queen's University [Belfast] (QUB), Oxford Regional Genetics Service, Churchill Hospital Oxford Centre for Haematology, All Wales Medical Genetics Services, Singleton Hospital, Clinical Genetics Department, St Michael's Hospital, North West Thames Regional Genetics Service, Kennedy-Galton Centre, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center [Kansas City, KS, USA], Clinical Molecular Genetics Laboratory, Fox Chase Cancer Center, Service de Génétique Oncologique, Institut Curie [Paris], Unité de génétique et biologie des cancers (U830), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de génétique, Institut Gustave Roussy (IGR), Variabilité Génétique et Maladies Humaines, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Consultation de génétique, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Service d'Oncologie Génétique, de Prévention et Dépistage, Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Service de Génétique Clinique Chromosomique et Moléculaire, CHU Saint-Etienne, Laboratoire de Génétique Chromosomique, CH Chambéry, Service de génétique [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Department of Internal Medicine, Huntsman Cancer Institute, Division of Population Science, Department of Cancer Biology, Dana-Farber Cancer Institute [Boston], Department of Surgery, Harvard Medical School [Boston] (HMS), Department of Epidemiology, Columbia University [New York], Centre for Molecular , Environmental, Genetic and Analytic (MEGA) Epidemiology, University of Melbourne-Centre for Molecular, Melbourne School of Population Health, Cancer Prevention Institute of California, entre for Molecular, Environmental, Genetic and Analytic (MEGA) Epidemiology, University of Melbourne, Department of Dermatology, University of Utah School of Medicine [Salt Lake City], Dept of OB/GYN and Comprehensive Cancer Center, Medizinische Universität Wien = Medical University of Vienna, Center for Genomic Medicine, Copenhagen University Hospital-Rigshospitalet [Copenhagen], Copenhagen University Hospital, Department of Pathology, University of Iceland [Reykjavik]-Landspitali - University Hospital, Epidemiology Research Program, American Cancer Society, Department of Environmental Medicine, New York University School of Medicine, NYU System (NYU)-NYU System (NYU)-NYU Cancer Institute, Clinical Genetics Service, Memorial Sloane Kettering Cancer Center [New York], Statistical and Data Center, Roswell Park Cancer Institute [Buffalo], Australia New Zealand (ANZGOG), Westmead Hospital [Sydney], Ohio State University [Columbus] (OSU), Evanston CCOP - NorthShore University Health System, University of Chicago, Southern Pines Women's Health Center, University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC)-University of North Carolina System (UNC), Sarasota Memorial Healthcare, Tufts Medical Center, Department of Molecular Virology, Immunology and Medical Genetics [Colombus], Ohio State University [Columbus] (OSU)-College of Medicine and Public Health [Colombus], Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, U.O.C. di Oncologia, Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University [Washington] (GU), Latvian Biomedical Research and Study Centre [Rīga], Genetic Counselling Unit, IDIBELL-Catalan Institute of Oncology, Molecular Diagnostic Unit, Department of Preventive Medicine, University of Southern California (USC)-Keck School of Medicine [Los Angeles], University of Southern California (USC), Department of Gynecologic Oncology, Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Department of Molecular Genetics, National Institute of Oncology, Cancer Research Initiatives Foundation, Sime Darby Medical Centre-Malaysia and University Malaya Cancer Research Institute-University Malaya Medical Centre, Jonsson Comprehensive Cancer Center at UCLA, Jonsson Comprehensive Cancer Center, UCSF Cancer Risk Program, University of California (UC), Departments of Medicine, Epidemiology, and Biostatistics, UCSF, Cancer Genetics Laboratory, University of Pretoria [South Africa], Oncogenetics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), The Hong Kong Hereditary Breast Cancer Family Registry, The University of Hong Kong (HKU), Department of Gynaecology and Obstetrics, University Hospital of Cologne [Cologne]-Centre of Familial Breast and Ovarian Cancer-Centre for Integrated Oncology (CIO), Institute for Medical Informatics, Statistics and Epidemiology [Leipzig] (IMISE), Universität Leipzig [Leipzig], Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Ludwig-Maximilians-Universität München (LMU), University Hospital of Schleswig-Holstein-Christian-Albrechts-Universität zu Kiel (CAU), University Hospital Düsseldorf-Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Westfälische Wilhelms-Universität Münster = University of Münster (WWU), Institute of Cell and Molecular Pathology, Hannover Medical School [Hannover] (MHH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Universitätsklinikum Ulm - University Hospital of Ulm, Julius-Maximilians-Universität Würzburg (JMU)-Centre of Familial Breast and Ovarian Cancer, Heidelberg University Hospital [Heidelberg], University Hospital Carl Gustav Carus, Universität Regensburg (UR), University Hospital Frankfurt a.M., Molecular Oncology Laboratory, Hospital Clínico San Carlos, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Hemato-oncology service, Hôpital du Sacré-Coeur de Montréal, Department of Population Sciences, Beckman Research Institute of City of Hope, Department of Laboratory Medicine and Pathology, Mayo Clinic, Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale Tumouri (INT)-Fondazione Istituto FIRC di Oncologia Molecolare, Unit of Medical Genetics, Fondazione IRCCS Istituto Nazionale Tumouri (INT), Division of Cancer Prevention and Genetics, Department of Experimental Oncology, Istituto Europeo di Oncologia-Consortium for Genomics Technology (Cogentech), Cancer Bioimmunotherapy Unit, IRCCS-Centro di Riferimento Oncologico, Università degli Studi di Firenze = University of Florence (UniFI), Department of Molecular Medicine, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Clinical Genetics Branch, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH), Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto-Cancer Care Ontario, Samuel Lunenfeld Research Institute, Mount Sinai Hospital [Toronto, Canada] (MSH), Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Laboratory Medicine, St Michael's Hospital-Keenan Research Centre of the Li Ka Shing Knowledge Institute [Toronto], Ontario Cancer Genetics Network, Cancer Care Ontario, Odense University Hospital, Department of Clinical Genetics [Copenhagen], Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Skejby Hospital, Department of Laboratory Medicine and Pathology and Health Sciences Research, This work was supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175), from the Canadian Institutes of Health Research for the 'CIHR Team in Familial Risks of Breast Cancer' program and by the Canadian Breast Cancer Research Alliance-grant #019511. This research was also supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defence Ovarian Cancer Idea award (W81XWH-10-1-0341) and grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure. ACA is a CR-UK Senior Cancer Research Fellow, DFE is CR-UK Principal Research Fellow, GCT is a NHMRC Senior Principal Research Fellow, J.S. is Chairholder of the Canada Research Chair in Oncogenetics, on behalf of CIMBA, SWE-BRCA, HEBON, EMBRACE, GEMO Study Collaborators and kConFab Investigators, European Project: 223175,EC:FP7:HEALTH,FP7-HEALTH-2007-B,COGS(2009), Pediatric Surgery, Neurology, Medical Oncology, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Roswell Park Cancer Institute [Buffalo] (RPCI), Universität Leipzig, Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Pennsylvania [Philadelphia]-Perelman School of Medicine, University of Pennsylvania [Philadelphia], Pomeranian Medical University-International Hereditary Cancer Centre, Radboud university [Nijmegen], University of Kansas Medical Center [Lawrence], Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Georgetown University, University of California, Westfälische Wilhelms-Universität Münster (WWU), Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU)-Centre of Familial Breast and Ovarian Cancer, Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], RS: GROW - School for Oncology and Reproduction, Genetica & Celbiologie, Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Human Genetics, CCA -Cancer Center Amsterdam, ARD - Amsterdam Reproduction and Development, Human genetics, and CCA - Oncogenesis

Subjects
Oncology, Medicin och hälsovetenskap, Estrogen receptor, Genome-wide association study, HORMONE-RELATED PROTEIN, Chromosomes, Human, Pair 9 - genetics, Medical and Health Sciences, 0302 clinical medicine, 610 Medical sciences Medicine, CDKN2A, Risk Factors, Genotype, INVESTIGATORS, Chromosomes, Human, Pair 12 - genetics, skin and connective tissue diseases, MAMMOGRAPHIC DENSITY, Medicine(all), 0303 health sciences, BRCA1 Protein, Middle Aged, BRCA2 Protein, 3. Good health, DNA-Binding Proteins, Hereditary Breast and Ovarian Cancer Syndrome - genetics, 030220 oncology & carcinogenesis, Hereditary Breast and Ovarian Cancer Syndrome, TUMOR SUBTYPES, Female, Chromosomes, Human, Pair 9, Research Article, Adult, Breast cancer, BRCA1, BRCA2, medicine.medical_specialty, Heterozygote, SUSCEPTIBILITY LOCI, Single-nucleotide polymorphism, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Polymorphism, Single Nucleotide, OVARIAN-CANCER, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, ddc:610, GENOME-WIDE ASSOCIATION, ddc:611, Genetic Association Studies, 030304 developmental biology, Aged, Gynecology, Chromosomes, Human, Pair 12, CONSORTIUM, BRCA1 Protein - genetics, ALLELES, medicine.disease, BRCA2 Protein - genetics, Cancer and Oncology, GENETIC MODIFIERS, Ovarian cancer, Transcription Factors
Abstract

INTRODUCTION: Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2). METHODS: To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers and analysed the associations with breast cancer risk within a retrospective likelihood framework. RESULTS: Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 x 10-4). The association was restricted to mutations proven or predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 x 10-5, P-difference = 0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 x 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049). CONCLUSIONS: The present findings, in combination with previously identified modifiers of risk, will ultimately lead to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2 mutation carriers., published_or_final_version

Published
2012
Full Text
View/download PDF

186. Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer

Author

Peter Hillemanns, Roger L. Milne, Chiun-Sheng Huang, Jan Lubinski, Arif B. Ekici, Rita K. Schmutzler, Julian Peto, Qin Wang, Rob A. E. M. Tollenaar, Børge G. Nordestgaard, Chen-Yang Shen, Paolo Radice, Nicola Miller, Barbara Burwinkel, Suleeporn Sangrajrang, Núria Malats, James McKay, Gianluca Severi, Ian Tomlinson, Dong-Young Noh, Irene L. Andrulis, Xiaoqing Chen, Esther M. John, Katarzyna Durda, Anna Marie Mulligan, Anne Lise Børrensen-Dale, Frederik Marmé, Simon S. Cross, Elza Khusnutdinova, Joerg Heil, Gillian S. Dite, Melissa C. Southey, Thilo Dörk, Peter Kraft, Monica Barile, Graeme Elliot, Olivia Fletcher, Yuri I. Rogov, Arto Mannermaa, Nazneen Rahman, Annegien Broeks, Susan E. Hankinson, Xianshu Wang, Natalia Bogdanova, Mark E. Sherman, Volker Harth, Johann H. Karstens, Montserrat Garcia-Closas, Robert Winqvist, Alfons Meindl, Rebecca Hein, Laura J. van't Veer, Stefan Nickels, Manjeet K. Humphreys, Valerie Gaborieau, Lorna Gibson, Jose Ignacio Arias Perez, Giuseppe Floris, Christa Stegmaier, Gord Glendon, Heiko Müller, Marjanka K. Schmidt, Jonine D. Figueroa, Julia A. Knight, Graham G. Giles, Siranoush Manoukian, Ming-Feng Hou, Albina Farahtdinova, Gilles Thomas, Diether Lambrechts, Anna Jakubowska, Paul D.P. Pharoah, Alexander Miron, Michael J. Kerin, Iosif V. Zalutsky, Ian W. Brock, Laura Baglietto, Argyrios Ziogas, Claus R. Bartram, John L. Hopper, Marina Bermisheva, Grethe I. Grenaker Alnæs, Jaana M. Hartikainen, Sei Hyun Ahn, Hermann Brenner, Paul Brennan, Dieter Flesch-Janys, Stephen J. Chanock, Robert N. Hoover, Fergus J. Couch, Georgia Chenevix-Trench, Anthony Renwick, Sheila Seal, Mervi Grip, Matthias W. Beckmann, Karin Leunen, Javier Benitez, Peter Schürmann, Vesa Kataja, Arja Jukkola-Vuorinen, Peter A. Fasching, David J. Hunter, Christian M. Bayer, Rogier A. Oldenburg, Karen A. Pooley, Antoinette Hollestelle, Hoda Anton-Culver, Veli-Matti Kosma, P. Zamora, Jonathan Beesley, Paolo Peterlongo, Darya Prokofieva, Keun-Young Yoo, Isabel dos Santos Silva, Katarzyna Jaworska, Janet E. Olson, Carmel Apicella, U Hamann, Jyh-Cherng Yu, Shan Wang-Gohrke, Natalia Antonenkova, Sara Lindström, Andreas Schneeweiss, Katri Pylkäs, Douglas F. Easton, Charlotte Lanng, Alison M. Dunning, Vessela N. Kristensen, Daehee Kang, Elinor J. Sawyer, Jolanta Lissowska, Christina Justenhoven, Zachary S. Fredericksen, Madeleine M.A. Tilanus-Linthorst, Angela Cox, Maartje J. Hooning, Volker Arndt, Christof Sohn, Betül T. Yesilyurt, Jenny Chang-Claude, Ellen L. Goode, Stig E. Bojesen, Clare Turnbull, Medical Oncology, Clinical Genetics, and Surgery

Subjects
Oncology, Epidemiology, Estrogen receptor, Noninfiltrating, Cohort Studies, 0302 clinical medicine, Risk Factors, Ductal, Receptors, common variants, Breast, Progesterone, risk, 0303 health sciences, subtypes, Carcinoma, Ductal, Breast, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Case-Control Studies, Chromosomes, Human, Pair 5, Female, Follow-Up Studies, Humans, Neoplasm Grading, Polymorphism, Single Nucleotide, Prognosis, Receptors, Estrogen, Receptors, Progesterone, Genetic Predisposition to Disease, Single Nucleotide, 3. Good health, 030220 oncology & carcinogenesis, alleles, Pair 5, Human, medicine.medical_specialty, Intraductal, Biology, Article, Chromosomes, 03 medical and health sciences, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, Progesterone receptor, medicine, Genetic predisposition, Carcinoma, Polymorphism, 030304 developmental biology, Gynecology, Case-control study, Ductal carcinoma, confer susceptibility, medicine.disease, Estrogen, genome-wide association, Histopathology
Abstract

Background: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. Methods: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. Results: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08–1.14, P = 7 × 10−18) for invasive breast cancer and 1.10 (95% CI = 1.01–1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR = 1.07, 95%CI = 0.99–1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)-positive disease (per-allele OR = 1.16, 95% CI = 1.12–1.20, P = 1 × 10−18 vs. OR = 1.03, 95% CI = 0.99–1.07, P = 0.2 for PR-negative disease; Pheterogeneity = 2 × 10−7); heterogeneity by ER status was not observed (P = 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) = 1.20 (1.14–1.25), 1.13 (1.09–1.16), and 1.04 (0.99–1.08) for grade 1, 2, and 3/4, respectively; Ptrend = 5 × 10−7]. Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. Impact: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants. Cancer Epidemiol Biomarkers Prev; 20(10); 2222–31. ©2011 AACR.

Published
2011
Full Text
View/download PDF

187. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations

Author

Domenico Delia, Paolo Radice, Gaia Roversi, Jiri Bartek, Jirina Bartkova, Simona Frigerio, Bernard Peissel, Daniele Lecis, Siranoush Manoukian, Manoukian, S, Peissel, B, Frigerio, S, Lecis, D, Bartkova, J, Roversi, G, Radice, P, Bartek, J, and Delia, D

Subjects
Cancer Research, Genes, BRCA2, Genes, BRCA1, CHEK2 breast cancer sarcoma, Breast Neoplasms, Gene mutation, Biology, Protein Serine-Threonine Kinases, medicine.disease_cause, Breast cancer, Germline mutation, Cell Line, Tumor, medicine, Humans, Genetic Predisposition to Disease, skin and connective tissue diseases, CHEK2, Alleles, Germ-Line Mutation, Genetics, Family Health, Mutation, Cancer, Sarcoma, Middle Aged, medicine.disease, Genes, p53, HCT116 Cells, Penetrance, Pedigree, Gene Expression Regulation, Neoplastic, Checkpoint Kinase 2, Oncology, Cancer research, Female, Haploinsufficiency
Abstract

CHEK2 gene mutations occur in a subset of patients with familial breast cancer, acting as moderate/low penetrance cancer susceptibility alleles. Although CHEK2 is no longer recognized as a major determinant of the Li-Fraumeni syndrome, a hereditary condition predisposing to cancer at multiple sites, it cannot be ruled out that mutations of this gene play a role in malignancies arising in peculiar multi-cancer families. To assess the contribution of CHEK2 to the breast cancer/sarcoma phenotype, we screened for germ-line sequence variations of the gene among 12 probands from hereditary breast/ovarian cancer families with one case of sarcoma that tested wild-type for mutations in the BRCA1, BRCA2, and TP53 genes. Two cases harbored previously unreported mutations in CHEK2, the c.507delT and c.38A>G, leading to protein truncation (p.Phe169LeufsX2) and amino acid substitution (p.His13Arg), respectively. These mutations were not considered common polymorphic variants, as they were undetected in 230 healthy controls of the same ethnic origin. While the c.38A>G encodes a mutant protein that behaves in biochemical assays as the wild-type form, the c.507delT is a loss-of-function mutation. The identification of two previously unreported CHEK2 variants, including a truncating mutation leading to constitutional haploinsufficiency, in individuals belonging to families selected for breast cancer/sarcoma phenotype, supports the hypothesis that the CHEK2 gene may act as a factor contributing to individual tumor development in peculiar familial backgrounds.

Published
2011

188. The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain

Author

Gianluca Severi, Melissa C. Southey, Fernando Mondaca Fernández, Monica Barile, Frederik Marmé, Paolo Peterlongo, Laura Caleca, Siranoush Manoukian, Javier Benitez, Anne Langheinz, Paolo Radice, Elisa Cattaneo, Fernando Ravagnani, María R Alonso, Laura Galastri, Loris Bernard, Valentina Dall'Olio, Laura Baglietto, C. Sohn, Bernard Peissel, Ana Osorio, Tiziana Bianchi, Fabrice Odefrey, Filomena Ficarazzi, Barbara Burwinkel, and Graham G. Giles

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, Population, Single-nucleotide polymorphism, Breast Neoplasms, Breast cancer, Internal medicine, medicine, Genetics, Humans, Genetic Predisposition to Disease, Allele, education, Genotyping, Genetics (clinical), education.field_of_study, business.industry, Lumpectomy, Case-control study, Australia, Genetic Variation, medicine.disease, Europe, MicroRNAs, Case-Control Studies, Female, business, Mastectomy
Abstract

The rare variant rs12975333 is a G→T change located at the eighth nucleotide of the mature microRNA-125a (miR-125a). The T allele has been reported to block the processing of pri-miRNA to pre-miRNA precursor and to be extremely rare, being detected only once in a panel of 1200 individuals from diverse ethnic backgrounds assessed by the Centre d'Etude du Polymorphisme Humain.1 A study by Li et al 2 showed the T allele of rs12975333 to be strongly associated with breast cancer risk, with 6 of 72 (8.3%) breast cancer cases from two hospitals in Antwerp, Belgium, being carriers of the T allele and none of 282 controls collected from the general population in the Antwerp area or 587 Caucasian controls collected in the USA.2 The breast cancers were all lymph node negative and received only local treatment (mastectomy or lumpectomy followed by radiation treatment). Genotyping was performed by means of the TaqMan assay, as previously described,1 using whole-genome-amplified DNA obtained from …

Published
2011

189. The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers

Author

Laura Papi, Mirko Riboni, Sara Volorio, Barbara Pasini, Gaia Roversi, Paolo Radice, Siranoush Manoukian, Paolo Peterlongo, Alessandra Viel, Aline Martayan, Irene Catucci, Paolo Verderio, Bernard Peissel, Monica Barile, Carla B. Ripamonti, Sara Pizzamiglio, Daniela Zaffaroni, Liliana Varesco, Giuseppe Giannini, Catucci, I, Verderio, P, Pizzamiglio, S, Manoukian, S, Peissel, B, Zaffaroni, D, Roversi, G, Ripamonti, C, Pasini, B, Barile, M, Viel, A, Giannini, G, Papi, L, Varesco, L, Martayan, A, Riboni, M, Volorio, S, Radice, P, and Peterlongo, P

Subjects
rs3834129, Risk, Cancer Research, Heterozygote, endocrine system diseases, Genotype, Population, BRCA mutation carriers, Genes, BRCA2, DNA Mutational Analysis, Genes, BRCA1, Breast Neoplasms, CASP8, Biology, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, medicine, Humans, Allele, Polymorphism, skin and connective tissue diseases, 10. No inequality, education, 030304 developmental biology, Proportional Hazards Models, 0303 health sciences, education.field_of_study, Breast cancer risk, Caspase 8, Polymorphism, Genetic, BRCA mutation, Cancer, medicine.disease, 3. Good health, Minor allele frequency, Oncology, Italy, 030220 oncology & carcinogenesis, Mutation, Cancer research, Proportional Hazards Model, Female, Breast disease, polymorphism, casp8, breast cancer risk, brca mutation carriers, Breast Neoplasm, Human
Abstract

The rs3834129 polymorphism, in the promoter of CASP8 gene, has been recently reported as associated with breast cancer risk in the general population, with the minor allele del having a protective effect. Some of the genetic variants found associated with breast cancer risk were reported as risk modifiers in individuals with mutations in BRCA1 and BRCA2 genes. Here, we tested the effect of the rs3834129 del allele on breast cancer risk in BRCA mutation carriers. The rs3834129 was genotyped in a total of 1,207 Italian female BRCA mutation carriers. Of these, 740 carried a BRCA1 mutation and 467 a BRCA2 mutation. Overall, 699 were affected with breast cancer and 508 were unaffected. When considering class 1 (loss-of-function) BRCA mutations, hazard ratios estimated by weighted multivariable Cox regression model, for individuals with at least one copy of the del allele, were 1.46 (95% confidence interval (CI): 1.08–1.99) for BRCA1 and BRCA2 mutation carriers combined, 1.74 (95% CI: 1.24–2.46) for BRCA1 mutation carriers, and 1.09 (95% CI: 0.66–1.80) for BRCA2 mutation carriers. These results suggest that the minor allele del of rs3834129 is associated under a dominant model with increased breast cancer risk in carriers of BRCA1 mutations but not in carriers of BRCA2 mutations.

Published
2011

190. Evidence for a link between TNFRSF11A and risk of breast cancer

Author

María E. Sáez, Javier Benitez, Conxi Lázaro, Adriana Lasa, Miguel Angel Pujana, Paolo Radice, Yael Laitman, Judith Balmaña, Núria Bonifaci, Pedro Pérez-Segura, Orland Diez, Trinidad Caldés, Bella Kaufman, Miguel de la Hoya, Eitan Friedman, Victor Moreno, Loris Bernard, Siranoush Manoukian, Joan Brunet, Ander Urruticoechea, Gaia Roversi, Teresa Ramón y Cajal, Fina Climent, Monica Barile, Roni Milgrom, María Dolores Miramar, Frederique Mariette, Pasquale Pellegrini, Bernard Peissel, Paolo Peterlongo, Ana Osorio, Daniela Zaffaroni, Alessandra Viel, Eva González-Suárez, Maria Teresa Soler, Marta Palafox, Ignacio Blanco, Bonifaci, N, Palafox, M, Pellegrini, P, Osorio, A, Benítez, J, Peterlongo, P, Manoukian, S, Peissel, B, Zaffaroni, D, Roversi, G, Barile, M, Viel, A, Mariette, F, Bernard, L, Radice, P, Kaufman, B, Laitman, Y, Milgrom, R, Friedman, E, Sáez, M, Climent, F, Soler, M, Diez, O, Balmaña, J, Lasa, A, Ramón y. Cajal, T, Miramar, M, De la Hoya, M, Pérez Segura, P, Caldés, T, Moreno, V, Urruticoechea, A, Brunet, J, Lázaro, C, Blanco, I, Pujana, M, and González Suárez, E

Subjects
Oncology, Heterozygote, Cancer Research, medicine.medical_specialty, BRCA1/2 mutation carriers, Colorectal cancer, Population, Proliferation, Breast Neoplasms, Genome-wide association study, Ligand, Biology, medicine.disease_cause, Colorectal-Cancer, RANK, Cohort Studies, Genome-Wide Association, Breast cancer, Internal medicine, Odds Ratio, medicine, Humans, Genetic Predisposition to Disease, education, Bone, BRCA2 Protein, education.field_of_study, Receptor Activator of Nuclear Factor-kappa B, BRCA1 Protein, Hazard ratio, TNFRSF11A, Rankl, Odds ratio, medicine.disease, Osteoclastogenesi, RANKL, Susceptibility, Differentiation, Mutation, Immunology, biology.protein, Female, Resolution, Carcinogenesis
Abstract

Intracellular signaling mediated by the receptor activator of nuclear factor-κB [Rank, encoded by the tumor necrosis factor receptor superfamily, member 11a (Tnfrsf11a) gene] is fundamental for mammary gland development in mice, regulating the expansion of stem and progenitor cell compartments. Conversely, Rank overexpression in mice promotes abnormal proliferation and impairs differentiation, leading to an increased incidence of tumorigenesis. Here, we show that a common genetic variant near the 5′-end of TNFRSF11A, rs7226991, is associated with breast cancer risk in the general population and among carriers of mutations in the breast cancer 2, early onset (BRCA2) gene. Akin to the results of the Cancer and Genetics Markers of Susceptibility initiative, combined analysis of rs7226991 in two Spanish case–control studies (1,365 controls and 1,323 cases in total) revealed a significant association with risk: odds ratio (OR) = 0.88, 95% confidence interval (CI) 0.78–0.98, P trend = 0.025. Subsequent examination of BRCA1 (n = 1,017) and BRCA2 (n = 885) mutation carriers revealed a consistent association in the latter group: weighted hazard ratio (wHR) = 0.70; 95% CI 0.55–0.88; and P trend = 0.003; compared to BRCA1 mutation carriers, wHR = 0.91; 95% CI 0.76–1.10; and P trend = 0.33. The results of this study need to be replicated in other populations and with larger numbers of BRCA1/2 mutation carriers.

Published
2011

191. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

Author

Thomas v O Hansen, Amanda B. Spurdle, Anne-Marie Gerdes, Sue Healey, Per Karlsson, Tomasz Huzarski, Mary B. Daly, Mary Porteous, T. Caldes, Ulf Kristoffersson, Ignacio Blanco, A. Miron, Laurence Faivre, Barbara Wappenschmidt, Laurence Venat-Bouvet, Marie Stenmark Askmalm, Olga M. Sinilnikova, Susan Peock, Alessandra Viel, Conxi Lázaro, Katherine L. Nathanson, Laurent Castera, Douglas F. Easton, Susan L. Neuhausen, Jan Lubinski, Phuong L. Mai, Virginie Moncoutier, Paolo Radice, Heli Nevanlinna, Christi J Asperen, Xianshu Wang, Brita Arver, Christian Sutter, Senno Verhoef, Rosette Lidereau, Mary S Beattie, Bjarni A Agnarsson, Ina Ruehl, Monica Barile, Bent Ejlertsen, Laura Ottini, Catherine Noguès, Jennifer A. Przybylo, Cinzia Casella, Trevor Cole, Norbert Arnold, Sandra Fert-Ferrer, Hilmi Ozcelik, Irene L. Andrulis, Susan M. Domchek, Valérie Bonadona, Kirsten B. Moysich, David E. Goldgar, Anna Jakubowska, Paul D.P. Pharoah, Beth Y. Karlan, Jenny Gross, Gaia Roversi, Tadeusz Dębniak, Hanne Meijers-Heijboer, Susan J. Ramus, Dorthe G. Crüger, Zachary S. Fredericksen, Siranoush Manoukian, Viviana Gismondi, Maria A. Caligo, Helene Holland, Laure Barjhoux, Gord Glendon, Ana Osorio, Jacques Simard, John L. Hopper, Mercedes Durán, Kristiina Aittomäki, Håkan Olsson, Mads Thomassen, Fabio Capra, Patrick J. Morrison, Britta Fiebig, Mary Beth Terry, Marinus J. Blok, Evgeny N. Imyanitov, Joseph Vijai, Javier Benitez, Mark T. Rogers, D. Gareth Evans, Helmut Deissler, Tomasz Byrski, Sylvie Mazoyer, Laura Papi, Dominique Stoppa-Lyonnet, Marco Montagna, Kenneth Offit, Cezary Cybulski, Dominique Leroux, Georgia Chenevix-Trench, Danielle Bodmer, Lucy Side, Margaret Cook, Ros Eeles, Alan Donaldson, Christiana Kartsonaki, Carole Brewer, Matti A. Rookus, Jacek Gronwald, Dorothea Gadzicki, Shirley Hodgson, Jonathan Beesley, Gabriella Pichert, Andrew K. Godwin, Dieter Niederacher, Yuan Chun Ding, Torben A Kruse, Paolo Peterlongo, Rita K. Schmutzler, Xiaoqing Chen, Annika Lindblom, Fergus J. Couch, Maaike P.G. Vreeswijk, Mark H. Greene, Esther M. John, Raymonda Varon-Mateeva, Simon A. Gayther, Margreet G. E. M. Ausems, Tomas Kirchhoff, Lars Jønson, Madeleine M. A. Tilanus-Linthorst, Ute Hamann, Marie-Agnès Collonge-Rame, Antonis C. Antoniou, M John Kennedy, Karin Kast, Theo A. M. van Os, Penny Soucy, Debra Frost, Alison M. Dunning, Daniela Zaffaroni, Anna Allavena, Maria-Isabel Tejada, Yves-Jean Bignon, Lesley McGuffog, Bohdan Górski, Åke Borg, Fabienne Prieur, Bernard Peissel, Helen Gregory, Clare Oliver, Saundra S. Buys, Ana Dutra-Clarke, Alfons Meindl, Ramunas Janavicius, Uffe Birk Jensen, Miguel de la Hoya, Ramus, S, Kartsonaki, C, Gayther, S, Pharoah, P, Sinilnikova, O, Beesley, J, Chen, X, Mcguffog, L, Healey, S, Couch, F, Wang, X, Fredericksen, Z, Peterlongo, P, Manoukian, S, Peissel, B, Zaffaroni, D, Roversi, G, Barile, M, Viel, A, Allavena, A, Ottini, L, Papi, L, Gismondi, V, Capra, F, Radice, P, Greene, M, Mai, P, Andrulis, I, Glendon, G, Ozcelik, H, Thomassen, M, Gerdes, A, Kruse, T, Cruger, D, Jensen, U, Caligo, M, Olsson, H, Kristoffersson, U, Lindblom, A, Arver, B, Karlsson, P, Stenmark Askmalm, M, Borg, A, Neuhausen, S, Ding, Y, Nathanson, K, Domchek, S, Jakubowska, A, Lubiński, J, Huzarski, T, Byrski, T, Gronwald, J, Górski, B, Cybulski, C, Dębniak, T, Osorio, A, Durán, M, Tejada, M, Benítez, J, Hamann, U, Rookus, M, Verhoef, S, Tilanus Linthorst, M, Vreeswijk, M, Bodmer, D, Ausems, M, van Os, T, Asperen, C, Blok, M, Meijers Heijboer, H, Peock, S, Cook, M, Oliver, C, Frost, D, Dunning, A, Evans, D, Eeles, R, Pichert, G, Cole, T, Hodgson, S, Brewer, C, Morrison, P, Porteous, M, Kennedy, M, Rogers, M, Side, L, Donaldson, A, Gregory, H, Godwin, A, Stoppa Lyonnet, D, Moncoutier, V, Castera, L, Mazoyer, S, Barjhoux, L, Bonadona, V, Leroux, D, Faivre, L, Lidereau, R, Nogues, C, Bignon, Y, Prieur, F, Collonge Rame, M, Venat Bouvet, L, Fert Ferrer, S, Miron, A, Buys, S, Hopper, J, Daly, M, John, E, Terry, M, Goldgar, D, Hansen, T, Jønson, L, Ejlertsen, B, Agnarsson, B, Offit, K, Kirchhoff, T, Vijai, J, Dutra Clarke, A, Przybylo, J, Montagna, M, Casella, C, Imyanitov, E, Janavicius, R, Blanco, I, Lázaro, C, Moysich, K, Karlan, B, Gross, J, Beattie, M, Schmutzler, R, Wappenschmidt, B, Meindl, A, Ruehl, I, Fiebig, B, Sutter, C, Arnold, N, Deissler, H, Varon Mateeva, R, Kast, K, Niederacher, D, Gadzicki, D, Caldes, T, de la Hoya, M, Nevanlinna, H, Aittomäki, K, Simard, J, Soucy, P, Spurdle, A, Holland, H, Chenevix Trench, G, Easton, D, Antoniou, A, Faculteit Medische Wetenschappen/UMCG, Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Klinische Genetica, Genetica & Celbiologie, RS: GROW - School for Oncology and Reproduction, Clinical Genetics, Pediatric Surgery, Human genetics, CCA - Oncogenesis, and Human Genetics

Subjects
Oncology, Cancer Research, endocrine system diseases, Genes, BRCA2, Genes, BRCA1, Genome-wide association study, FAMILIES, 0302 clinical medicine, Risk Factors, Retrospective Studie, Genotype, Odds Ratio, skin and connective tissue diseases, POPULATION, Genetics, Ovarian Neoplasms, Aged, 80 and over, Allele, 0303 health sciences, education.field_of_study, Likelihood Functions, Articles, GERMLINE MUTATIONS, Middle Aged, Likelihood Function, female genital diseases and pregnancy complications, 3. Good health, 030220 oncology & carcinogenesis, Female, Chromosomes, Human, Pair 9, Human, Adult, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], medicine.medical_specialty, Heterozygote, SUSCEPTIBILITY LOCI, PROTEINS, Population, Biology, Polymorphism, Single Nucleotide, BASONUCLIN-2, 03 medical and health sciences, Breast cancer, Germline mutation, SDG 3 - Good Health and Well-being, Internal medicine, medicine, BREAST-CANCER, Humans, GENOME-WIDE ASSOCIATION, education, Alleles, Germ-Line Mutation, 030304 developmental biology, Retrospective Studies, Aged, IDENTIFICATION, Risk Factor, Ovarian Neoplasm, Editorials, Cancer, medicine.disease, Minor allele frequency, Ovarian cancer
Abstract

[Background]: Germline mutations in the BRCA1 and BRCA2 genes are associated with increased risks of breast and ovarian cancers. Although several common variants have been associated with breast cancer susceptibility in mutation carriers, none have been associated with ovarian cancer susceptibility. A genome-wide association study recently identified an association between the rare allele of the single-nucleotide polymorphism (SNP) rs3814113 (ie, the C allele) at 9p22.2 and decreased risk of ovarian cancer for women in the general population. We evaluated the association of this SNP with ovarian cancer risk among BRCA1 or BRCA2 mutation carriers by use of data from the Consortium of Investigators of Modifiers of BRCA1/2. [Methods]: We genotyped rs3814113 in 10 029 BRCA1 mutation carriers and 5837 BRCA2 mutation carriers. Associations with ovarian and breast cancer were assessed with a retrospective likelihood approach. All statistical tests were two-sided. [Results]: The minor allele of rs3814113 was associated with a reduced risk of ovarian cancer among BRCA1 mutation carriers (per-allele hazard ratio of ovarian cancer = 0.78, 95% confidence interval = 0.72 to 0.85; P = 4.8 × 10-9) and BRCA2 mutation carriers (hazard ratio of ovarian cancer = 0.78, 95% confidence interval = 0.67 to 0.90; P = 5.5 × 10-4). This SNP was not associated with breast cancer risk among either BRCA1 or BRCA2 mutation carriers. BRCA1 mutation carriers with the TT genotype at SNP rs3814113 were predicted to have an ovarian cancer risk to age 80 years of 48%, and those with the CC genotype were predicted to have a risk of 33%. [Conclusion]: Common genetic variation at the 9p22.2 locus was associated with decreased risk of ovarian cancer for carriers of a BRCA1 or BRCA2 mutation., Spanish National Cancer Center (CNIO) and the Spanish Consortium: Partially supported by Fundación Mutua Madrileña, Asociación Española Contra el Cáncer, and the Spanish Ministry of Science and Innovation (FIS PI08 1120).

Published
2011
Full Text
View/download PDF

192. Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

Author

Celine M. Vachon, Irene L. Andrulis, Peter Schürmann, Arja Jukkola-Vuorinen, Manjeet K. Humphreys, Lorna Gibson, Natalia Bogdanova, Jean Wang, Annika Lindblom, Marjanka K. Schmidt, Annegien Broeks, Ian W. Brock, A. Miron, Janet E. Olson, James McKay, Michael J. Kerin, Gilles Thomas, Anna González-Neira, Ian Tomlinson, Jaana M. Hartikainen, Anna Marie Mulligan, P. A. Fasching, Gillian S. Dite, I dos Santos Silva, Keun-Young Yoo, Rebecca Hein, Michael Bremer, Thilo Dörk, Ji Arias Pérez, C. R. Bartrar, Sara Margolin, Javier Benitez, Jo Knight, Suleeporn Sangrajrang, Alison M. Dunning, Matthias W. Beckmann, Rita K. Schmutzler, Julian Peto, John L. Hopper, Natalia Antonenkova, Angela Cox, Yuri I. Rogov, Barbara Burwinkel, Robert N. Hoover, L.J. van 't Veer, Nicola F. Johnson, Fergus J. Couch, Jenny Chang-Claude, Arto Mannermaa, Ute Hamann, Hoda Anton-Culver, Douglas F. Easton, Jolanta Lissowska, Graeme Elliott, Vesa Kataja, Montserrat Garcia-Closas, Elinor J. Sawyer, Alfons Meindl, Kristen N. Stevens, Peter Hillemanns, Veli-Matti Kosma, R.A.E.M. Tollenaar, Thomas Brüning, Stephen J. Chanock, Zachary S. Fredericksen, Carmel Apicella, Laura Baglietto, Mervi Grip, Roger L. Milne, James R. Cerhan, Karen A. Pooley, Paolo Peterlongo, Matthew L. Kosel, Daehee Kang, Argyrios Ziogas, Arif B. Ekici, Yon-Dschun Ko, Shan Wang-Gohrke, Graham G. Giles, Alexander Hein, Xianshu Wang, Bernardo Bonanni, Gianluca Severi, Loris Bernard, P Pharoah, Dong-Young Noh, Xiaoqing Chen, Esther M. John, Melissa C. Southey, K. Pylkäs, Robert Winqvist, Vernon S. Pankratz, Catriona McLean, Georgia Chenevix-Trench, J. V. Zalutsky, David J. Hunter, Siranoush Manoukian, Simon S. Cross, Gordon Glendon, V. Gabrieau, and Paul Brennan

Subjects
Oncology, poor-prognosis, medicine.medical_specialty, Cancer Research, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Biology, Germline, 03 medical and health sciences, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, Breast cancer, Polymorphism (computer science), Internal medicine, Neoplasms, medicine, Genetic predisposition, Genetic susceptibility, ovarian, Humans, Genetic Predisposition to Disease, gene, 030304 developmental biology, 0303 health sciences, pten loss, Oncogene, pathway, Case-control study, pik3ca mutations, association, Cancer, Genetic Variation, Genetics and Genomics, Odds ratio, correlate, medicine.disease, 3. Good health, Association study, high-frequency, 030220 oncology & carcinogenesis, Case-Control Studies, Immunology, Female
Abstract

BACKGROUND: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene and risk of breast cancer. METHODS: A single-nucleotide polymorphism from the PIK3CA locus that was associated with breast cancer in a study of Caucasian breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) study and in 30 949 cases and 29 788 controls from the Breast Cancer Association Consortium (BCAC). RESULTS: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white Europeans combined (odds ratio (OR) = 0.97, 95% confidence interval (CI) 0.95-0.99, P = 4.6 x 10(-3)), but did not reach significance in the BCAC replication study alone (OR = 0.98, 95% CI 0.96-1.01, P = 0.139). CONCLUSION: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer British Journal of Cancer (2011) 105, 1934 - 1939. doi: 10.1038/bjc.2011.448 www.bjcancer.com Published online 27 October 2011 (C) 2011 Cancer Research UK

Published
2011

193. No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women

Author

Siranoush Manoukian, Paolo Radice, Xiaoqing Chen, Monica Barile, Georgia Chenevix-Trench, Sharon E. Johnatty, Jonathan Beesley, Paolo Peterlongo, Valeria Pensotti, and Amanda B. Spurdle

Subjects
Oncology, Adult, Cancer Research, medicine.medical_specialty, Adolescent, Single-nucleotide polymorphism, Breast Neoplasms, Biology, Polymerase Chain Reaction, Polymorphism, Single Nucleotide, White People, Young Adult, Breast cancer, Risk Factors, Internal medicine, Genotype, medicine, SNP, Humans, Genetic variability, skin and connective tissue diseases, ABCC11, Aged, Aged, 80 and over, Cerumen, Cancer, DNA, Neoplasm, Middle Aged, medicine.disease, Prognosis, Endocrinology, Case-Control Studies, biology.protein, ATP-Binding Cassette Transporters, Female, Breast disease
Abstract

ABCC11 is an ATP-binding cassette transporter responsible for the transport of a diverse range of lipophilic compounds. A single nucleotide polymorphism (SNP) encoding an amino acid change has recently been shown to determine whether cerumen (earwax) is wet or dry. We hypothesised that this ABCC11 SNP may be associated with breast cancer risk because an association has been reported between wet earwax and increased risk of breast cancer. We therefore analysed the frequency of the functional SNP in 1342 cases and 2256 controls from two breast cancer studies of Caucasian women but found no evidence for an association with breast cancer risk.

Published
2010

194. Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer

Author

Mia M. Gaudet, Tomas Kirchhoff, Todd Green, Joseph Vijai, Joshua M. Korn, Candace Guiducci, Ayellet V. Segrè, Kate McGee, Lesley McGuffog, Christiana Kartsonaki, Jonathan Morrison, Sue Healey, Olga M. Sinilnikova, Dominique Stoppa-Lyonnet, Sylvie Mazoyer, Marion Gauthier-Villars, Hagay Sobol, Michel Longy, Marc Frenay, GEMO Study Collaborators, Frans B. L. Hogervorst, Matti A. Rookus, J. Margriet Collée, Nicoline Hoogerbrugge, Kees E. P. van Roozendaal, HEBON Study Collaborators, Marion Piedmonte, Wendy Rubinstein, Stacy Nerenstone, Linda Van Le, Stephanie V. Blank, Trinidad Caldés, Miguel de la Hoya, Heli Nevanlinna, Kristiina Aittomäki, Conxi Lazaro, Ignacio Blanco, Adalgeir Arason, Oskar T. Johannsson, Rosa B. Barkardottir, Peter Devilee, Olofunmilayo I. Olopade, Susan L. Neuhausen, Xianshu Wang, Zachary S. Fredericksen, Paolo Peterlongo, Siranoush Manoukian, Monica Barile, Alessandra Viel, Paolo Radice, Catherine M. Phelan, Steven Narod, Gad Rennert, Flavio Lejbkowicz, Anath Flugelman, Irene L. Andrulis, Gord Glendon, Hilmi Ozcelik, OCGN, Amanda E. Toland, Marco Montagna, Emma D'Andrea, Eitan Friedman, Yael Laitman, Ake Borg, Mary Beattie, Susan J. Ramus, Susan M. Domchek, Katherine L. Nathanson, Tim Rebbeck, Amanda B. Spurdle, Xiaoqing Chen, Helene Holland, kConFab, Esther M. John, John L. Hopper, Saundra S. Buys, Mary B. Daly, Melissa C. Southey, Mary Beth Terry, Nadine Tung, Thomas V. Overeem Hansen, Finn C. Nielsen, Mark H. Greene, Phuong L. Mai, Ana Osorio, Mercedes Durán, Raquel Andres, Javier Benítez, Jeffrey N. Weitzel, Judy Garber, Ute Hamann, Susan Peock, Margaret Cook, Clare Oliver, Debra Frost, Radka Platte, D. Gareth Evans, Fiona Lalloo, Ros Eeles, Louise Izatt, Lisa Walker, Jacqueline Eason, Julian Barwell, Andrew K. Godwin, Rita K. Schmutzler, Barbara Wappenschmidt, Stefanie Engert, Norbert Arnold, Dorothea Gadzicki, Michael Dean, Bert Gold, Robert J. Klein, Fergus J. Couch, Georgia Chenevix-Trench, Douglas F. Easton, Mark J. Daly, Antonis C. Antoniou, David M. Altshuler, and Kenneth Offit

Subjects
Genetics, QH426-470
Published
2010

195. A BRCA1 promoter variant (rs11655505) and breast cancer risk

Author

Sara Pizzamiglio, Filomena Ficarazzi, Christoph Engel, Rita K. Schmutzler, Barbara Burwinkel, Amanda B. Spurdle, Melissa C. Southey, Jonathan Beesley, Paolo Peterlongo, Monica Barile, John L. Hopper, Barbara Wappenschmidt, Paolo Verderio, Georgia Chenevix-Trench, Paolo Radice, Siranoush Manoukian, Peter Bugert, and Xiaoqing Chen

Subjects
Oncology, medicine.medical_specialty, Genes, BRCA1, Single-nucleotide polymorphism, Genome-wide association study, Breast Neoplasms, Biology, Polymorphism, Single Nucleotide, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Genetics, medicine, Humans, Genetic Predisposition to Disease, Risk factor, skin and connective tissue diseases, Promoter Regions, Genetic, Genetics (clinical), 030304 developmental biology, 0303 health sciences, BRCA1 Protein, Case-control study, Cancer, medicine.disease, 3. Good health, Minor allele frequency, Endocrinology, Logistic Models, 030220 oncology & carcinogenesis, Case-Control Studies, Female, Breast disease, Genome-Wide Association Study
Abstract

Background A study of Chinese women recently suggested that the minor allele of rs11655505 in the BRCA1 promoter (c.–2265C→T) increases promoter activity and has a protective effect on breast cancer risk. Methods We genotyped rs11655505 in 2912 female breast cancer cases and 2783 unaffected female controls from four Caucasian breast cancer studies. Results No evidence for an association between rs11655505 and breast cancer risk was found. Conclusions Our study failed to confirm a role of rs11655505 in breast cancer risk. Larger studies are necessary to determine if there is a weak association between this SNP and breast cancer risk.

Published
2010

196. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility

Author

Milena S. Nicoloso, Paolo Radice, Fernando Ravagnani, Hyunsoo Kim, Sylwia E. Wojcik, Hao Sun, Priyankara Wickramasinghe, Xuemei Wang, Siranoush Manoukian, Jana Ferdin, Tanja Kunej, Riccardo Spizzo, Lianchun Xiao, Ramana V. Davuluri, Giorgio Secreto, Carlo M. Croce, George A. Calin, and Masayoshi Shimizu

Subjects
Cancer Research, Single-nucleotide polymorphism, MiRNA binding, Breast Neoplasms, Biology, Polymorphism, Single Nucleotide, Article, Cell Line, Tumor, microRNA, Gene expression, Gene silencing, Humans, Genetic Predisposition to Disease, RNA, Messenger, Allele, Gene, 3' Untranslated Regions, Alleles, Regulation of gene expression, Genetics, Binding Sites, Genome, Human, Gene Expression Regulation, Neoplastic, MicroRNAs, Oncology, Case-Control Studies, Female, 5' Untranslated Regions
Abstract

Single-nucleotide polymorphisms (SNP) associated with polygenetic disorders, such as breast cancer (BC), can create, destroy, or modify microRNA (miRNA) binding sites; however, the extent to which SNPs interfere with miRNA gene regulation and affect cancer susceptibility remains largely unknown. We hypothesize that disruption of miRNA target binding by SNPs is a widespread mechanism relevant to cancer susceptibility. To test this, we analyzed SNPs known to be associated with BC risk, in silico and in vitro, for their ability to modify miRNA binding sites and miRNA gene regulation and referred to these as target SNPs. We identified rs1982073-TGFB1 and rs1799782-XRCC1 as target SNPs, whose alleles could modulate gene expression by differential interaction with miR-187 and miR-138, respectively. Genome-wide bioinformatics analysis predicted ∼64% of transcribed SNPs as target SNPs that can modify (increase/decrease) the binding energy of putative miRNA::mRNA duplexes by >90%. To assess whether target SNPs are implicated in BC susceptibility, we conducted a case-control population study and observed that germline occurrence of rs799917-BRCA1 and rs334348-TGFR1 significantly varies among populations with different risks of developing BC. Luciferase activity of target SNPs, allelic variants, and protein levels in cancer cell lines with different genotypes showed differential regulation of target genes following overexpression of the two interacting miRNAs (miR-638 and miR-628-5p). Therefore, we propose that transcribed target SNPs alter miRNA gene regulation and, consequently, protein expression, contributing to the likelihood of cancer susceptibility, by a novel mechanism of subtle gene regulation. Cancer Res; 70(7); 2789–98

Published
2010

197. Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1

Author

Graeme Suthers, Danielle C. Vaz, Siranoush Manoukian, Rafael D. Mesquita, Paolo Radice, Carla B. Ripamonti, Marcelo A. Carvalho, Scott Grist, Jennifer Beddor, Maria A. Pino, Rachel Karchin, Åke Borg, Martha Godinho-Netto, Blase Billack, Mara Colombo, Alvaro N.A. Monteiro, Renato Santos Rodarte, Richard Rosenquist, and Viviane A. Monteiro

Subjects
Male, Models, Molecular, Health, Toxicology and Mutagenesis, Blotting, Western, Mutation, Missense, Biology, medicine.disease_cause, Transfection, Article, Frameshift mutation, Cell Line, Exon, Germline mutation, Genetics, medicine, Missense mutation, Humans, Computer Simulation, Frameshift Mutation, Molecular Biology, Genetic testing, Sequence Deletion, Mutation, medicine.diagnostic_test, Models, Genetic, BRCA1 Protein, Cancer, Computational Biology, Exons, medicine.disease, Pedigree, Protein Structure, Tertiary, Female, Common disease-common variant
Abstract

Germline mutations that inactivate BRCA1 are responsible for breast and ovarian cancer susceptibility. One possible outcome of genetic testing for BRCA1 is the finding of a genetic variant of uncertain significance for which there is no information regarding its cancer association. This outcome leads to problems in risk assessment, counseling and preventive care. The purpose of the present study was to functionally evaluate seven unclassified variants of BRCA1 including a genomic deletion that leads to the in-frame loss of exons 16/17 (Delta exons 16/17) in the mRNA, an insertion that leads to a frameshift and an extended carboxy-terminus (5673insC), and five missense variants (K1487R, S1613C, M1652I, Q1826H and V1833M). We analyzed the variants using a functional assay based on the transcription activation property of BRCA1 combined with supervised learning computational models. Functional analysis indicated that variants S1613C, Q1826H, and M1652I are likely to be neutral, whereas variants V1833M, Delta exons 16/17, and 5673insC are likely to represent deleterious variants. In agreement with the functional analysis, the results of the computational analysis also indicated that the latter three variants are likely to be deleterious. Taken together, a combined approach of functional and bioinformatics analysis, plus structural modeling, can be utilized to obtain valuable information pertaining to the effect of a rare variant on the structure and function of BRCA1. Such information can, in turn, aid in the classification of BRCA1 variants for which there is a lack of genetic information needed to provide reliable risk assessment.

Published
2008

198. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases

Author

Giovanna De Vecchi, Paolo Peterlongo, Loris Bernard, Sara Pizzamiglio, Siranoush Manoukian, Sara Volorio, Paolo Radice, Paolo Verderio, Fernando Ravagnani, and Valeria Pensotti

Subjects
Adult, Cancer Research, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, Biology, medicine.disease_cause, Germline, Breast cancer, Polymorphism (computer science), Risk Factors, medicine, Humans, Genetic Predisposition to Disease, Allele, skin and connective tissue diseases, Aged, Genetics, Aged, 80 and over, Mutation, Polymorphism, Genetic, BRCA mutation, Haplotype, Middle Aged, medicine.disease, Oncology, Haplotypes, Female, Tumor Suppressor Protein p53, Ovarian cancer
Abstract

Background : Germline disease-causing mutations in BRCA1 and BRCA2 genes confer high risk of breast and ovarian cancer, but account approximately for only 15% of familial cases. Theoretical models and experimental observations have indicated that the remaining familial aggregations would be explained by low-penetrance alleles. Moreover, alleles acting as genetic modifiers would modulate the breast cancer risk in carriers of BRCA mutations. The Ins16bp and Arg72Pro polymorphisms of p53 were implicated in breast cancer and recently it has been shown that these polymorphisms could have an effect when combined as specific haplotypes. Here, we investigated the possible role of the Ins16bp and Arg72Pro polymorphisms and their haplotypes as low-penetrance alleles in familial breast cancer. Methods : The Ins16bp and Arg72Pro polymorphisms were genotyped in a total of 350 familial index cases affected with breast cancer and negative for mutations in BRCA genes, and 352 controls. The Ins16bp and Arg72Pro polymorphisms were studied separately, and as haplotypes and haplotypes combinations. Results : None of the performed analyses resulted statistically significant. Conclusions : These observations suggested that neither the Ins16bp or Arg72Pro polymorphisms considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.

Published
2008

199. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases

Author

M. Giarola, Virna De Benedetti, Michele Sardella, Mara Colombo, Carla B. Ripamonti, Paolo Radice, Luigi Mariani, Bernard Peissel, Silvana Pilotti, Siranoush Manoukian, Marco Losa, Marco A. Pierotti, Colombo, Mara, Giarola, Monica, Mariani, Luigi, Ripamonti, Carla B., De Benedetti, Virna, Sardella, Michele, Losa, Marco, Manoukian, Siranoush, Peissel, Bernard, Pierotti, Marco A., Pilotti, Silvana, and Radice, Paolo

Subjects
Oncology, Adult, medicine.medical_specialty, Pathology, endocrine system diseases, Cyclin D, Estrogen receptor, Breast Neoplasms, Adenocarcinoma, Pathology and Forensic Medicine, Diagnosis, Differential, Germline mutation, Cyclin D1, Internal medicine, Cyclins, Progesterone receptor, medicine, Biomarkers, Tumor, Humans, skin and connective tissue diseases, Pathological, BRCA2 Protein, Family Health, Apoptosis Regulatory Protein, biology, BRCA1 Protein, Middle Aged, BRCA1, BRCA2, Cyclin, BRCAX, biology.protein, Cancer research, Immunohistochemistry, Female, Familial breast cancer, Apoptosis Regulatory Proteins, Breast Neoplasm, Immunostaining, Human
Abstract

Most familial breast cancers arise in patients who tested negative for germline mutations in BRCA1 and BRCA2 genes (also referred to as BRCAX cases). Several studies aimed to define histopathological and molecular profiles characteristic of BRCA1, BRCA2 and BRCAX tumors have been performed. Major pathological and immunohistochemical differences have been reported in BRCA1 cancers compared to the other two groups, whereas less difference has been observed between BRCA2 and BRCAX cases. The aim of this study was to investigate the ability of selected tumor markers to discriminate BRCAX breast cancers from cancers arising in carriers of mutations in BRCA genes, and their usefulness in selecting familial cases in whom testing for such mutations is more likely to result uninformative. We carried out a morphological and immunohistochemical analysis on 22 BRCA1, 16 BRCA2 and 33 BRCAX familial breast cancers. Age at first diagnosis, histological type and grade, and immunostaining for estrogen receptor (ER), progesterone receptor (PR), p53, HER2/Neu, E-cadherin and cyclin D1 were investigated. The occurrence of somatic mutations of the TP53 gene was also verified. BRCA1 tumors resulted clearly distinguishable from BRCAX cases, occurring at a younger age, being more frequently of higher grade, negative for ER, PR and cyclin D1 expression and positive for p53 alterations. The predictive value of age at diagnosis, histological grade and PR expression was confirmed in a multivariable analysis. When comparing BRCA2 with BRCAX tumors, the only parameter that differed was cyclin D1, which was significantly overexpressed in BRCA2 cases both in the univariable and the multivariable analyses. If confirmed by further studies, our observations indicate that the investigation of cyclin D1 expression in familial breast cancer cases could be used, in conjunction with the analysis of other tumor markers preferentially associated with BRCA1 or BRCA2 tumors, to prioritize hereditary cases for mutation testing in BRCA genes. © 2008 USCAP, Inc All rights reserved.

Published
2008

200. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases

Author

Monica Barile, Siranoush Manoukian, Paolo Radice, Marco A. Pierotti, Stefano Fortuzzi, Sara Pizzamiglio, Giovanna De Vecchi, Paolo Peterlongo, Fernando Ravagnani, and Paolo Verderio

Subjects
Oncology, Adult, Aged, 80 and over, Cancer Research, medicine.medical_specialty, Caspase 8, Polymorphism, Genetic, business.industry, Promoter polymorphism, Age at diagnosis, Breast Neoplasms, Middle Aged, medicine.disease, Young Adult, Breast cancer, Internal medicine, medicine, Humans, Female, Familial breast cancer, business, Promoter Regions, Genetic, Aged
Published
2008

Catalog

Books, media, physical & digital resources
See catalog results